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SPRING CLEANING
This photo captures the soft misty colors of an early spring 
morning, in Xitang, Jiaxing, China, where women work laundry 
by the river side. 
The image focuses on the woman with most action. The 
outfocused leaves of the willow tree in the foreground frames the 
subjects in action. In the background, an outfocused watermill is 
seen.  
This is very much the atmosphere of traditional water village life 
in rural China. 
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Cancer Treatment in the 
Era of Targeted Therapy: 
the March is on!
Dr. James CS CHIM
In general, cancers including haematological cancers are characterised 
by either of the following three mechanisms: 1. activation of 
oncogenes; 2. loss of function of tumour suppressor genes or 3. 
inhibition of cellular differentiation.1,2 Oncogenes confer proliferative 
or survival advantages while tumour suppressors normally prevent 
development of cancer by activating apoptosis.  Therefore, cancer 
cells often have constitutive activation of oncogenes together with 
inactivation of tumour suppressor genes.  On the other hand, failure 
of proper differentiation of precursor cells may result in cancers.
Haematological cancers comprise cancers arising from lymphoid 
(lymphoma, acute lymphoblastic leukaemia, chronic lymphocytic 
leukaemia and multiple myeloma) or myeloid origin (acute myeloid 
leukaemias [AML] and chronic myeloid leukaemias [CML], 
myelodysplastic syndrome). Many either arise from progenitors 
or stem cells that are naturally residing in the bone marrow or 
metastasise to the bone marrow (lymphoma, multiple myeloma). 
On the other hand, solid cancers arise from transformed epithelium 
including carcinomas of the breast, lung, liver and colon. 
Basic research has enormously impacted the modern management of 
both haematological and solid cancers. Because of the understanding 
of the molecular pathogenesis of cancers that usually involve 
concomitant activation of oncogenes and inactivation of tumour 
suppressor genes, numerous therapeutic targets have been identified 
in cancers. For instance, imatinib, a tyrosine kinase inhibitor, is the 
first small molecule found to inhibit the pathogenic fusion gene, 
BCR/ABL, which is the primary oncogenic event in chronic myeloid 
leukaemia. Indeed, since the first randomised controlled trial, the 
International Randomized Study of Interferon and STI571 (IRIS) trial, 
published in 2003,3 which showed a much higher rate of response 
(both haematological and cytogenetic) in CML patients randomised 
to receive imatinib. Moreover, a substantial number of patients 
receiving imatinib may actually achieve molecular remission, which 
has been a mission impossible with conventional chemotherapy. 
Indeed the updated survival for patients enrolled in that trial 
showed that the 8-year overall survival is 80% in patients receiving 
imatinib,4 which is comparable or superior to survivals achieved 
by the use of allogeneic haematopoietic stem cell transplantation 
in young CML patients transplanted with stem cells from an HLA-
identical sibling. Because of the significant response rate including 
molecular remission and the remarkable survival associated with the 
use of imatinib, allogeneic HSCT is no longer the first line therapy 
in CML patients but reserved for patients with accelerated phase 
or blastic transformation. Moreover, while intensive chemotherapy 
or allogeneic HSCT is only applicable in relatively young patients, 
imatinib and many other targeted therapies are generally non- 
myelotoxic or minimally myelotoxic, and hence can be used in both 
young and elderly patients alike. Therefore, the scale of impact of the 
advent of targeted therapy has been enormous, and the momentum 
is still on. Other major targeted therapies in haematological 
cancers include the monoclonal antibodies such as rituximab and 
alemtuzumab, and small molecules like bortezomib, which is an 
nuclear factor kappa B inhibitor and very effective in the treatment 
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of myelomas and lymphomas. Moreover, epigenetic 
therapy has come of age too. Epigenetics refers to the 
alteration of gene expression not associated with gene 
mutation but due to either promoter DNA methylation 
or histone modifications at the promoter regions of 
tumour suppressor genes. Demethylating therapy such 
as 5-Azacitidine (Vidaza) or Decitabine (Dacogen) is 
now the choice of therapy in patients suffering from 
myelodysplastic syndrome, a disease of the elderly 
characterised by peripheral cytopenia and a propensity 
of leukaemia transformation. Indeed, 5-azacytidine has 
been shown to result in less transfusion requirements, 
increased response rate, and hence better quality of life. 
Moreover, it also suppresses leukaemia transformation, 
and hence improves overall survival. 
Similar advances have been made in solid cancers too.5 
For instance, therapeutic antibodies have emerged 
as an important part of treatment in multiple solid 
cancers. In breast cancer, trastuzumab is a welcome 
addition to the treatment of HER2-overexpressing 
breast cancers. In colorectal cancer, cetuximab, an 
inhibitor of EGFR signalling, has been shown to be 
useful in metastatic colorectal cancers and head and 
neck cancers. Similarly, small molecules have made 
substantial impact in cancer therapy too. For instance, 
in bronchogenic carcinoma, the era of targeted therapy 
has come for the treatment of non-small cell lung 
cancers, best exemplified by the story of epidermal 
growth factor receptor inhibitors like gefitinib (Iressa) 
and erlotinib (Tarceva) in addition to anti-angiogenesis. 
Moreover, the future of lung cancer treatment will 
certainly rest on a personalised approach with more 
molecularly targeted agents on the horizon. Finally, in 
hepatocellular carcinoma, a cancer highly associated 
with hepatitis B infection, which is a prevalent disease 
in Hong Kong, this has been met with astounding 
success with the use of multiple kinase inhibitors like 
sorafenib and sunitinib.6 
Therefore, the emergence of targeted therapy has 
markedly improved the treatment outcome of both 
haematological and epithelial cancers. We look 
forward to further improvement with the emergence 
of new targeted therapies, or after optimisation of their 
use in different phases of treatment such as the role of 
maintenance therapy with targeted therapy, or their 
role in combination with chemotherapy or even with 
other targeted therapies. Therefore, the march is on!
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Dermatological Quiz
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Private Dermatologist
Dr. Lai-yin CHONG  
This 20-year-old man had refractory acne which failed to respond 
to treatments with various oral antibiotics. He had been given oral 
isotretinoin at a dose of 1mg/kg/day (Body weight: 60kg). After 2 weeks’ 
treatment, his condition deteriorated and he developed extensive painful 
and haemorrhagic papulo-nodular lesions over his upper trunk (Fig 1) 
and face. There was no systemic upset.
Questions:
1.What is your preliminary diagnosis?
2.What are the main differential diagnoses?
3.How can this condition be prevented in practice? 
4.What are the important systemic side-effects of oral isotretinoin that  
   must be monitored? Fig 1:  Multiple haemorrhagic crusted lesions 
over the upper back
(See P. 41 for answers)
Dermatological Quiz
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Multiple myeloma is  a  cancer with multi focal 
proliferation of plasma cells in the bone marrow1. 
Plasma cells are important in normal immune defence 
because of its ability to produce immunoglobulin, which 
is responsible for defence against offensive micro-
organisms. Patients with myeloma often present with 
bone pain, fractures and high blood calcium levels, 
resulting in impairment of kidney function, anaemia 
and infection.
Diagnosis of myeloma is based on the demonstration of 
excessive (>10%) plasma cells in the marrow, presence 
of monoclonal gammopathy and lytic bone lesions 
on X-ray. The disease is incurable, mainly due to the 
low complete remission (CR) rate (used to be in the 
region of 5%). Therefore, the main goal of treatment 
used to be symptomatic relief. This has been achieved 
with combination chemotherapy with melphalan and 
prednisolone. (Figure 1) 
Figure 1. Myeloma is characterised by the presence of excessive 
plasma cells in the marrow. (Upper panel showing abnormal 
plasma cells infiltrating the marrow) Clinically, osteolytic bone 
lesions may manifest as pathological fractures (arrow in the lower 
panel points to a fracture beneath the head of humerus).
Pathogenesis involves immortalisation of a post-
germinal centre B-lymphocyte, which homes to the 
bone marrow. Upon interaction with the marrow 
stroma, a paracrine cytokine loop involving IL-6 
and IGF1 is triggered, which confers survival and 
proliferative advantage to the neoplastic plasma 
cell2. At this stage, clinically the disease manifests as 
monoclonal gammopathy of unknown significance 
(MGUS), which transforms into clinically myeloma at 
the rate of 1% per year. At the early stage, myeloma 
plasma cells rely on the marrow micro-environment for 
its survival2. However, upon acquisition of secondary 
genetic alterations or mutations including FGFR3 
mutation, secondary translocations involving MYC, 
etc, the myeloma plasma cells will be able to survive in 
extramedullary sites and manifest as extramedullary 
plasmacytoma or plasma cell leukaemia. (Figure 2) 
Figure 2. Myeloma pathogenesis starts with immortalisation 
of a post-germinal centre plasma cell (GC), which homes to the 
marrow and manifests clinically as monoclonal gammopathy 
of unknown significance (MGUS). When these plasma cells 
metastasise to different parts of the bone marrow, the disease 
manifests as intramedullary myeloma (IMM). Upon acquisition 
of secondary genetic mutations such as RAS or MYC mutations 
or secondary translocations involving MYC, the plasma cells 
may reside in extramedullary sites, and clinically manifest as 
extramedullary myeloma (EMM) including plasma cell leukaemia 
or extramedullary plasmacytoma. 
Major advances in the recent decade include the advent 
of autologous bone marrow transplantation and targeted 
therapy, which result in a much higher complete 
remission (CR) rate1. Autologous haematopoietic stem 
cell transplantation (auto-HSCT) is performed after 
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adequate initial control of myeloma by the use of 
chemotherapy that results in substantial eradication 
of tumour cells. This is followed by mobilisation and 
collection of stem cells from the patients, after which, 
the patients will undergo high-dose chemotherapy, 
and then infusion of stem cells collected earlier on, 
which is the essence of auto-HSCT). Targeted therapy 
(including bortezomib, thalidomide or lenalidomide) 
enables effective killing of myeloma tumour cells, and 
hence results in a high CR rate in particular those with 
bortezomib -containing regimens1. Moreover, unlike 
chemotherapy, targeted therapy is not toxic to the 
marrow, and hence can be used in both young and old 
patients alike. Finally, initial control of myeloma can be 
substantially increased by the combination of targeted 
therapy together with chemotherapy. Therefore, 
targeted therapy alone may result in a CR rate of about 
20+%. The use of auto-BMT results in an additional CR 
rate of 20+%. Therefore, the CR rate will be increased to 
up to 50% if myeloma patients are treated with targeted 
therapy initially, followed by auto-HSCT. 
In Hong Kong, we have shown in an earlier study 
that use of targeted therapy for initial disease control, 
followed by auto-HSCT, results in a CR rate of 48% 
(compared with 5% in the past)3. Moreover, 75% of 
patients survive at 4 years from diagnosis, compared 
with 40% for myeloma patients not receiving targeted 
therapy or auto-BMT4. One important finding from this 
study was that this CR rate (48%) and overall survival 
(75% at 4 years) were comparable to large studies in the 
US and UK while only 52% patients required the use of 
the expensive targeted therapy, bortezomib. Therefore, 
it is a strategy potentially able to maintain a high CR 
rate and favourable survival with a much lower cost. 
Finally, there is substantial evidence that targeted 
therapy may overcome the adverse impact of high-
risk cytogenetic alterations including deletions 
of chromosome 13, i.e. del(13), or the short arm 
of chromosome 17, i .e. del(17p), and reciprocal 
translocations between chromosomes 4 and 14, t(4;14) 
or translocations between chromosomes 14 and 16, 
t(14;16). (Figure 3) Patients carrying these chromosomal 
alterations have a low CR rate and a poor survival 
because of more drug resistant cases and more frequent 
relapse of disease5. Therefore, targeted therapy will 
be an important component of therapy for myeloma 
patients carrying high-risk cytogenetic features. For 
instance, in a French randomised controlled trial 
in which newly diagnosed myeloma patients were 
randomised to receive the conventional combinational 
chemotherapy regimen, VAD (vincristine, adriamycin 
and dexamethasone), or targeted therapy, bortezomib 
and dexamethasone (velcade/dexamethasone), it was 
shown that bortezomib/dexamethasone treated patients 
had similar CR rates and survivals in patients with or 
without del(13) or t(4;14)/t(14;16). On the other hand, in 
patients randomised to receive velcade/dexamethasone 
only, the CR rate and survival of patients carrying 
these high-risk chromosomal alterations were much 
inferior to those without. These finding testify that 
the incorporation of targeted therapy had overcome 
the adverse impact of these high risk chromosomal 
alterations in myeloma, and hence is particularly 
important as a frontline therapy in myeloma patients 
with high-risk chromosomal aberrations.
Figure 3. FISH study of myeloma marrow showing loss of one 
chromosome 13, i.e. del(13), and hence there is only one chromosome 
13 signal in the two marrow plasma cell while there are two 
signals in the adjacent normal myeloid cell.
In Hong Kong, as bortezomib is an expensive drug, 
in order to make judicious use of it and maximise its 
clinical benefit, one possible way is to risk-stratify the 
patients. Therefore, bortezomib should be used as a 
frontline therapy in myeloma patients carrying these 
high-risk chromosomal aberrations including del(13), 
t(4;14) or t(14;16). However, to execute this cost-effective 
treatment approach, there are several hurdles to further 
improve myeloma treatment in Hong Kong at present. 
First, the high-risk cytogenetic alterations can only be 
detected by a special technique called Fluorescent In-
situ Hybridisation (FISH), which is an expensive test 
currently unavailable for myeloma patients in HA 
hospitals. Secondly, frontline use of targeted therapy, 
especially bortezomib, which is approved y the FDA 
for frontline treatment of myeloma, is not possible in 
the HA setting yet. Therefore, it will be important to 
make the FISH test available for myeloma patients. 
As targeted therapy has been shown to overcome the 
adverse prognostic impact of the high-risk cytogenetic 
alterations, it is important to treat these patients with 
frontline bortezomib -containing regimens, followed by 
auto-HSCT in those transplant-eligible patients. With 
the current financial constraints, judicious frontline use 
of targeted therapy with bortezomib-based regimens 
in high-risk myeloma patients does not only benefit the 
patients (as it increases the CR rate, and also reduces 
risk of relapse, and hence improves the quality-of-
life of patients) but will also be cost-effective from the 
healthcare financing perspective as these “high-risk” 
myeloma patients are the ones who will progress/relapse 
quickly and require frequent hospital admissions for 
further disease and symptomatic control. Frontline use 
of bortezomib -based regimens in myeloma patients 
with high-risk cytogenetic features will translate into 
reduced hospital admissions and hence less hospital 
expenditure. Therefore, despite that myeloma is an 
incurable disease, significant advances have been made. 
Moreover, judicious frontline application of bortezomib 
-based therapy will be a cost-effective approach, and 
hence, the FISH test should be made freely available to 
all myeloma patients in the HA setting.
In addition, advances are being developed or actively 
sought in diagnostic techniques and imaging. To 
address developments in these different sectors, the 
Hong Kong Society of Myeloma has been established in 
March, 2010 to arouse public awareness of the disease, 
Medical BulletinVOL.16  NO.3  MARCH  2011
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Questions 1-10: Please answer T (true) or F (false) 
Please return the completed answer sheet to the Federation Secretariat on or before 31 March 2011 for 
documentation. 1 CME point will be awarded for answering the MCHK CME programme (for non-specialists) 
self-assessment questions. 
1.  Myeloma is a neoplastic proliferation of lymphocytes like lymphoma.
2.  The elevated monoclonal immunoglobulin leads to an enhanced immunity and protection against infections.
3.   Myeloma is now a curable disease.
4.  MGUS is a precursor of symptomatic myeloma.
5.  Extramedullary myeloma usually only occurs at advanced stage of myeloma.
6.  Autologous haematopoietic stem cell transplantation may increase the complete remission rate and prolong  
 survival of myeloma patients.
7.  Targeted therapy could only be applied to younger myeloma patients.
8.  Karyotypic aberration detected by Fluorescent In-situ Hybridisation (FISH) is an important prognostic factor  
 to myeloma patients.
9.  Targeted therapy like bortezomib may overcome the adverse prognostic impacts of high-risk karyotypic   
     abnormalities like del(13) or t(4;14).
10.  If targeted agents like bortezomib could be used upfront, autologous haematopoietic stem cell transplantation  
 might be omitted even in transplant-eligible patients.
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educate oncologists about latest advances in myeloma, 
and improve patient care in the whole of Hong Kong. In 
summary, to make judicious use of expensive targeted 
drugs in myeloma, it is important to make FISH test 
available to all myeloma patients, and bortezomib-based 
therapy should be used upfront in those carrying high-
risk chromosomal aberrations such as del(13), t(4;14) 
and t(14;20).   
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The Myelodysplastic Syndrome (MDS)
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Myelodysplastic Syndrome (MDS) is a group of 
malignant haematopoietic disorders sharing an 
ineffective production of one or more myeloid cell lines 
with a variable percentage of leukaemic blasts. There is 
usually a discrepancy between a cellular marrow and 
peripheral cytopenia with a risk of transformation to 
acute myeloid leukaemia (AML). It is primarily a disease 
affecting the elderly with a median age of 76 years old1 
at diagnosis. Clinically, it may overlap with a number of 
disease entities including aplastic anaemia, paroxysmal 
nocturnal haemoglobinuria (PNH), large granular 
lymphocytic (LGL) leukaemia and myeloproliferative 
neoplasms (MPN).
Classification
According to the 2008 revised WHO classification2, a 
new subtype is refractory cytopenia with unilineage 
dysplasia (RCUD) which includes: Refractory anaemia 
(RA) (unilineage erythroid dysplasia), refractory 
neutropenia (RN) (unilineage dysgranulopoiesis), 
and refractory thrombocytopenia (RT) (unilineage 
dysmegakaryocytopoiesis). (Table 1)
Table 1: 2008 WHO Classification of MDS
Subtype Blood Bone Marrow
(1) Refractory 
cytopenia with 
unilineage dysplasia 
(RCUD): RA/RN/RT
Single or bicytopenia Dysplasia in ≥ 10% 
of one cell line, < 5% 
blasts
(2) Refractory anaemia 
with ring sideroblasts 
(RARS)
Anaemia, no blasts ≥ 15% of erythroid 
precursors with ring 
sideroblasts, erythroid 
dysplasia only, <5% 
blasts
(3) Refractory 
cytopenia with 
multilineage 
dysplasia (RCMD)
Cytopenia(s), 
<1 x 109/L monocytes
Dysplasia in ≥ 
10% of cells in ≥ 
2 haematopoietic 
lineages +/- 15% ring 
sideroblasts, < 5% 
blasts
(4) Refractory anaemia 
with excess blasts-1 
(RAEB-1)
Cytopenia(s), ≤ 
2-4% blasts, < 1x /L 
monocytes
Unilineage or 
multilineage 
dysplasia, no Auer 
rods, 5-9% blasts
(5) Refracatory 
anaemia with excess 
blasts-2 (RAEB-2)
Cytopenia(s), 5-19% 
blasts, <1x 109/L 
monocytes
Unilineage or 
multilineage 
dysplasia, +/- Auer 
rods, 10-19% blasts
(6) Myelodysplastic 
Syndrome, 
unclassified (MDS-U)
Cytopenias Unilineage dysplasia 
or no dysplasia but 
characteristic MDS 
cytogenetics,  <  5% 
blasts
(7) MDS associated 
with isolated del(5q)
Anaemia, platelets 
normal or increased
Unilineage erythroid 
dysplasia, isolated del 
(5q), < 5% blasts
Work-up
D i a g n o s i s  o f  M D S  wa s  e s t a b l i s h e d  b a s e d  o n 
morphological examination of the peripheral blood 
and bone marrow. Patients with significant cytopenias 
and karyotypes t(8;21), t(15;17) and/or inversion 16 or 
variants should be considered to be suffering from AML. 
Special tests may be required in certain circumstances: 
(a) HLA tissue typing if the patient is a candidate of 
haemopoietic stem cell transplant (HSCT). (b) HLA-
DR15 positivity is potentially predictive for determining 
the responsiveness to immunosuppressive therapy (IST), 
particularly in young patients with normal cytogenetics 
and hypoplastic MDS (c) Flow cytometry to evaluate 
the presence of PNH clone or to assess the existence of 
LGL leukaemia (d) Genetic screening for patients with 
family history of cytopenias e.g. Fanconi anaemia or 
dyskeratosis congenita.
Prognosis
Survival and risk of AML transformation are predicted 
by the International Prognostic Scoring System (IPSS) 3 
and the World Health Organization Prognostic Scoring 
System (WPSS) 4.
The IPSS was based on the French-American-British 
(FAB) morphologic criteria and thus marrow blasts of 
21-30% was included in the prognostic variable which 
was previously classified as Refractory anaemia with 
excess blasts in transformation (RAEB-t). Based on the 
three prognostic variables: marrow blasts, karyotype 
and cytopenia, the patient can be sub-divided into 4 
risk categories according to the summation of the scores 
(Table 2). There is a wide range of median survival and 
risk of AML progression in between the 4 different risk 
categories (Figure 1, Table 3). Among the individual 
risk categories, there is also significant inferiority in the 
median survival if the patient's age is above 60.
Table 2: IPSS Score value (Cytopenia: Hb <10g/dL; ANC < 1800/
uL, platelet < 100,000/uL)
Prognositic 
variable
0 0.5 1.0 1.5 2.0
(1) Marrow 
blasts %
<5% 5-10% -- 11-20% 21-
30%
(2) Karyotype Good 
[normal, -Y 
alone, del 
(5q) alone, 
del(20q) 
alone]
Intermediate
(Others)
Poor 
(complex 
ie. ≥ 3 
bnormalilties 
or 
chromosome 
7 anomalies)
-- --
(3) Cytopenia 0/1 2/3 -- -- --
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Figure 1: Median Survival (IPSS)
Table 3: Median Survival and AML Progression Risk (in years) 
by IPSS and Age
Age (n) Low 
(score 0)
Int-1
(Score 0.5-1.0)
Int-2
(Score 1.5-2.0)
High
(Score ≥ 2.5)
All ages (816) 5.7 3.5 1.2 0.4
<60 (205) 11.8 5.2 1.8 0.3
>60 (611) 4.8 2.7 1.1 0.5
25% AML 
progression 
(in years) 
without therapy
9.4 3.3 1.1 0.2
Recently, the WPSS incorporates the WHO-based 
morphologic categories, the IPSS cytogenetic categories 
and the patient's RBC transfusion dependence (Table 4). 
As opposed to 4 different risk groups in IPSS, patients 
can be sub-divided into 5 risk groups. Once again, 
the individual patient can be risk categorised with 
significant differences in overall survival and AML 
progression risks (Table 5). Yet, whether WPSS is a 
better prognostic tool than IPSS remains to be seen.
Table 4: WPSS score value
Parameter 0 1 2 3
WHO category RA, RARS, 5q- RCMD, RCMD-RS RAEB-1 RAEB-2
Karyotype (same 
as IPSS)
Good Intermediate Poor --
RBC transfusion 
requirement (≥ 1  
RBC transfusion 
every 8 weeks 
over a 4 month 
period)
No Regular -- --
Table 5: Median overall survival (OS) in months and AML 
progression risk (WPSS)
WPSS Risk 
Group
WPSS Score Median OS 
(months)
AML Progression 
(Cumulative Probability)
2 year 5 year
Very low 0 141 0.03 0.03
Low 1 66 0.06 0.14
Intermediate 2 48 0.21 0.33
High 3-4 26 0.38 0.54
Very high 5 9 0.80 0.84
Management
The patient's IPSS risk category, patient's age, 
performance status, co-morbidities are important issues 
in considering the different therapeutic options for 
an individual patient. The WPSS provides a dynamic 
estimation of prognosis during the monitoring of the 
patient.
(A) Supportive Care
Supportive care includes red cell transfusions for 
symptomatic anaemia or platelet transfusions for 
severe thrombocytopenia or symptomatic bleeding. 
Granulocyte colony stimulating factor (G-CSF) may 
be considered for recurrent episodes of neutropenic 
fever. For patients with chronic red cell transfusion, 
serum ferrit in levels and corresponding organ 
dysfunction should be monitored, especially in the low 
or intermediate-1 risk group who has a much longer 
survival and lesser risk of AML transformation. In 
general, iron chelation therapy should be considered 
in low or intermediate-1 patients who have received 
or anticipated to receive more than 20 units of red cell 
transfusion with a serum ferritin level of more than 
1000ng/ml.
(B) Drugs
Currently, 3 drugs: Azacitidine, Decitabine and 
Lenalidomide were approved by the U.S. Food and 
Drug Administration (FDA) specifically for MDS-related 
indications (Table 6).
Table 6: Drugs approved by FDA for treatment of MDS
Azacitidine Lenalidomide Decitabine
Indication All MDS subtypes 
(FAB classificatioin): 
IPSS Int-1 or above
Low risk 
MDS(IPSS low or 
intermediate-1) 
with del(5q) 
and transfusion 
dependence
All MDS subtypes 
(FAB classification), 
IPSS: Int-1 or above
Route Subcutanous/
Intravenous
Oral Intravenous
Dosing 75mg/m2/day for 7 
days every 28 days
10mg/day for 21 to 
28 days every 28 
days 
20mg/m2 daily 
infusion over 5 days 
every 28 days
Mode of 
action
DNA 
hypomethylation
Immune 
modulation 
Angiogenesis 
inhibition
DNA 
hypomethylation
(I) Erythropoiesis Stimulating Agent (ESA)
For lower risk MDS patients, when the patient develops 
transfusion dependence, ESA should be considered. 
However, not all patients benefit from ESA. In the 
study by Hellstrom-Lindberg5, predictors of response 
included (i) <2 units red cell transfusion monthly and 
(ii) low baseline serum EPO level: < 500IU). There was 
a 74% chance of response compared with only 7% if 
the patient had high transfusion requirement and high 
baseline EPO level. 
(II) Immunosuppressive Therapy (IST)
Again for lower risk MDS patients, IST in the form of 
cyclosporine A or Antithymocyte globulin (ATG) should 
be considered if there is a good probability of response: 
IPSS low/int-1, WPSS very low, low or intermediate, age 
less than 60, hypocellular marrow, HLA-DR15 or PNH 
clone positivity. However, if the patient lacks the above 
predictors to ESA and IST, hypomethylating agents 
should be considered early in the treatment plan.
(III) Hypomethylating Agents
(i) Epigenetics
Epigenetics is genetic information that is not conveyed 
through DNA sequence. There are 2 important 
epigenetic processes: DNA methylation and histone 
modifications. The former involves addition of methyl 
group to cytidine in DNA, resulting in reduced gene 
expression or gene silencing. DNA methylation typically 
occurs in a CpG dinucleotide context. Unmethylated 
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CpGs are grouped in clusters called CpG islands that 
are present in the promoter regions of many genes. 
Both azacitidine and decitabine exert their effects by 
binding to and inactivating the DNA methyltransferase 
1 (DNMT1), leading to hypomethylation of DNA.
(ii) Azacitidine
T h e  e f f i c a c y  o f  A z a c i t i d i n e  ( 7 5 m g / m 2/ d a y ) 
subcutaneously for 7 days every 28 days in MDS has 
been shown in the pivotal phase III crossover study 
(9221)6 conducted by the Cancer and Leukaemia Group 
B (CALGB). There were 99 and 92 patients randomised 
to the azacitidine group and supportive care group 
respectively. All MDS subtypes were included. A 
significantly greater number of patients achieved an 
overall response (complete response + partial response 
+ haematological improvement or clinical benefit) in 
the azacitidine arm compared to the group receiving 
only supportive care (60% Vs 5% respectively, p <0.001). 
Differences were also seen in patients who crossed 
over to azacitidine, with 47% of patients responding. 
A number of different quality of life (QoL) parameters, 
fatigue and dyspnoea also showed improvement in 
the azacitidine treated group (Figure 2). Time to AML 
progression or death was longer in the azacitidine 
group (21 vs 12 months in supportive group, p=0.007). 
However, no significant overall survival advantage 
for azacitidine was demonstrated, probably due to the 
crossover effect for the supportive care group and the 
mixed MDS population.
Figure 2: EORTC fatigue, dyspnoea and physical functioning 
of crossover patients on supportive care for 4 months prior to 
crossover (n=30)
The median number of cycles from first treatment with 
azacitidine to any response was 3 cycles (range: 1 to 17 
cycles). For the responders, 75% responders achieved 
a response by cycle 4, 90% by cycle 6, the rest up to 
cycle 17. Thus, patients should receive at least 6 cycles 
of therapy before the azacitidine was withdrawn and 
considered to be non-beneficial.
In the AZA-001 Phase III study7, higher–risk MDS 
patients, FAB-defined as RAEB, RAEB-T, or CMML 
10-29% marrow blasts) with an IPSS of Int-2 or High 
were enrolled. Before randomisation, investigators 
pre-selected patients to 1 of the 3 Conventional Care 
Regiments (CCR): BSC only (transfusions, antibiotics, 
and G-CSF for neutropenic infections); low-dose ara-C 
(LDAC, 20mg/m2/day x 14 days, every 28 days): or 
standard chemotherapy (conventional induction/
consolidation). Patients were stratified by FAB/IPSS 
and randomised to Azacitidine (75mg/m2/day for 7 
days every 28 days) or CCR. The trial did not allow 
erythropoietin. Three hundred and fifty eight patients 
were randomised to Azacitidine (N=179) or CCR 
(N=179): BSC only (N=105, 58%), LDAC (N=42, 27%), or 
standard chemotherapy (N=25, 14%). Median age was 
69 years (range: 38-88). Azacitidine was administered 
for a median of 9 cycles, LDAC for 4 cycles. Azacitidine 
showed a median Kaplan-Meier overall survival time of 
24.4 months against 15.0 months with CCR (Figure 3). 
At 2 years, there was a 2-fold overall survival advantage: 
Azacitidine (51%) against CCR (26%). Median overall 
survival per IPSS cytogenetic subgroup showed similar 
results (Table 7).
Figure 3: Overall survival (Azacitidine Vs CCR) of AZA-001 
study
Table 7: OS analysis per IPSS Cytogenetic Group
Group % (n/N 
patients)
Azacitidine 
Median 
(months)
CCR 
Median 
(months)
HR (95% 
CI)
Log-rank p
Good 46 (166/358) Not reached 17.1 0.61 (0.39, 
0.96)
0.030
Intermediate 21 (76/358) 26.3 17.0 0.43 (0.21, 
0.88)
0.017
Poor 28 (100/358) 17.2 6.0 0.52 (0.32, 
0.87)
0.011
When analysed by International Working Group (IWG) 
best response, all response categories including stable 
disease (SD) showed an OS benefit with AZA treatment: 
CR (96.7%), PR (85.5%), HI (96%), or SD (73.3%), while 
only 28.6% of AZA patients with disease progression 
(DP) were alive at 1 year.8 This data showed that 
achievement of CR is not an obligate state for extended 
survival in higher-risk MDS.
(iii) Decitabine
Decitabine was developed in 1964 and was once 
explored in the management of  AML. Being a 
hypomethylating agent, its activity is similar to that of 
azacitidine
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In a multicentre phase III trial in advanced MDS, 
patients were randomised to receive supportive care 
plus decitabine (n=89) or supportive care alone (n=81)9, 
the overall response rate was 17% in the decitabine 
group compared to 0% in the supportive care group 
(p<0.001). Decitabine was delivered at a dose of 15mg/
m2 every 8 hours over 3 days (a total of 9 doses), 
with a cycle repeated every 6 weeks. Using the IWG 
criteria, complete response and partial response rates 
were 9% and 8% respectively in the decitabine group. 
An additional 13% of those receiving decitabine had 
haematological improvement, making the overall 
improvement rates of 30% in the decitabine group 
versus 7% in the supportive care group (p<0.001).
A more user friendly and less myelotoxic dosing 
schedule: Decitabine 20mg/m2 daily infusion over 5 
days every 28-day cycle has been explored in higher 
risk patients with a median of > 5 cycles. Ninety-nine 
patients10 (IPSS score of 0.5 or above) were enrolled; the 
ORR was 32%, and the overall improvement rate was 
51%, which included 18% haematological improvement. 
Similar response rates were observed in all FAB 
subtypes and IPSS risk categories. Among patients who 
improved, 82% demonstrated responses by the end of 
cycle 2. Among 33 patients assessable for a cytogenetic 
response, 17 (52%) experienced cytogenetic CR (n = 11) 
or partial response (n = 6). 
(iv) Lenalidomide
Lenalidomide is a 4-amino-glutarimide analog of 
thalidomide. In the MDS-003 phase II study10, it is 
given at a dose of 10mg/day for a 28 days cycle or 
10mg/day for 21 days of a 28 days cycle to the lower-
risk transfusion dependent MDS with the del(5q) 
abnormality. Among the 148 patients enrolled, 67% 
achieved transfusion independence, including every 
patient who experienced a cytogenetic response. The 
median haemoglobin increase from baseline was 5.2g/
dL. The cytogenetic CR rate was 45% (including some 
patients with complex karyotypes) and the median 
response duration was more than 2 years.
(C) Allogeneic Stem Cell Transplantation
Although majority of patients belong to the elderly 
group with co-morbidities, a minority of younger 
patients should be considered to be candidate of stem 
cell transplantation for potential cure. Important 
determinants include age,  performance status 
and availability of donor. The role of induction 
chemotherapy and hypomethylating agent before 
transplantation has not been well established.
In conclusion, MDS is a very heterogeneous disease and 
the management should be individualised according to 
the risk category (Table 8)
(i) Lower-risk MDS (RA, RARS, RCUD, RCMD, 
MDS-U, MDS del(5q), IPSS low, Int-1): The aim is 
to sustain residual haematopoiesis with minimising 
transfusions and improving QoL
(ii) Higher-risk MDS (RAEB-1, RAEB-2, IPSS Int-2, 
high): The aim is to achieve response, delaying 
AML transformation, prolonging survival and 
improving QoL. 
Meanwhile, supportive care should be provided to all 
MDS patients.
Table 8: Management of MDS based on risk-category
IPSS: Low/Int-1 
RA, RARS, RCUD, RCMD, 
MDS-U, MDS del(5q)
IPSS: Int-2/High
RAEB-1, RAEB-2
Treatment Goal Haematopoiesis Survival
Clinical Endpoint Haematological improvement 
Quality of life
Alter natural history 
Delay AML 
transformation
Management 
Considerations
Erythropoiesis stimulating agent
Immunosuppressive therapy
Hypomethylating agent
Hypomethylating 
agent Allogeneic SCT 
Chemotherapy
Supportive Iron chelation
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Introduction
Acquired aplastic anaemia (AA) is an unusual form of 
marrow failure with pancytopenia and a hypocellular 
bone marrow with no increase in reticulin. By definition, 
other causes of marrow failure must be excluded, 
especially malignant diseases of the haematopoietic 
system and cancer of other organs metastatic to the 
marrow. The most important differential diagnoses 
are between aplastic anaemia and hypocellular 
myelodysplasia. The widely accepted Camitta criteria 
defined for Severe Aplastic Anaemia (SAA) are: absolute 
neutrophil count (ANC) below 1.0 x 109/l, platelet 
count (PLT) below 20 x 109/l, reticulocyte count (Retic) 
below 0.1 percent, and less than 20 percent cellularity 
on trephine bone marrow biopsy.1 Such patients have 
little chance of spontaneous recovery and a very high 
mortality. Symptoms of anaemia: fatigue, palpitation, 
dyspnoea or mucocutaneous haemorrhage: ecchymoses, 
gingival bleeding, epistaxis lead to the initial medical 
consultation.
Epidemiology and Aetiology 
The annual incidence of aplastic anaemia in Europe was 
established in a large international study at 2 to 4 per 
million.2 The incidence in Thailand is 4 per million and 
closer to 6 in some rural regions of the country.3 The 
median age of onset is 20 - 25 years. Men and women 
are equally affected. The Thailand study also showed 
that low socio-economic status was associated with an 
increased risk of AA. The study pointed out that the 
low socio-economic status could well be the  surrogate 
marker for other environmental factors. An industry-
based national survey in Japan found the annual 
incidence of 14 per million of the population.4 The 
average incidence rate of 2.1 per million per year was 
the only local data published in 1998.5  
 
Aplastic anaemia is a disorder with a manifestation of a 
variety of insults which result in bone marrow failure. 
In about one-third of the patients with acquired AA, 
suspicion may be directed to a particular agent, usually 
a drug or virus. Table 1 indicates the drugs where the 
association with AA is strong.1 An association with 
viral infections, particularly hepatitis, has also been 
suggested, but how remains very vague.6 Thus, in at 
least two-thirds of patients, no aetiological agent can be 
identified. Japanese workers have found an association 
between a particular DR2 haplotype and response to 
cyclosporin therapy. It may be that there are subtle 
genetic associations with the disease and indeed it 
would be expected that a certain genetic make-up 
would render an individual susceptible to the varying 
environmental stress.7 What these environmental 
stresses are remains unknown.
Pathophysiology 
Marrow failure in aplastic anaemia could be the 
consequence of damage either to haematopoietic cells 
or to the cells from the microenvironment. However, 
most of the evidence points strongly to effects on 
haematopoietic cells, stromal cell function and growth 
factor production are normal in almost all patients with 
AA.  The important pathophysiologic inferences have 
been derived from clinical observation: the success of 
stem cell transfer focused attention on a haematopoietic 
deficit; recovery after antithymocyte globulin (ATG) and 
cyclosporin implied an immune mechanism of marrow 
destruction.  Cytotoxic T lymphocytes is likely one of 
the mediated component in causing marrow failure.8 
However, so far an increase in these cell types or their 
direct implication in marrow suppression has not been 
demonstrated. It is possible that cytokines such as 
interferon gamma may be released inappropriately in 
AA and suppresses bone marrow function. The large 
numbers of clinical associations with AA suggest that 
a variety of events can activate the immune system to 
cause marrow destruction and haematopoietic failure. 
Mutations in genes of the telomere repair complex have 
been reported in some adults with acquired AA. Some 
observations suggest that AA thus is a model of genetic 
factors interacting with environment, resulting in organ 
failure and malignant transformation.8 
Treatment for Severe Aplastic Anaemia 
Prompt diagnosis is important; both to treat the 
serious consequences of pancytopenia and to initiate 
treatment to correct the underlying bone marrow 
failure. Patients with moderate cytopenia, not requiring 
transfusions can be offered supportive care or out-
patient treatment with anabolic steroids and/or low 
dose steroids or cyclosporin. Patients with cytopenia 
requiring transfusions should be treated with either 
immunosuppressive therapy or haematopoietic stem 
cell transplant.9 Age and severity of cytopenia affect the 
choice of treatment. 
(1) Supportive Care  
The major cause of death in AA patients is infection. 
The major risk factor for developing infection is the 
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degree and duration of the neutropenia. When the 
patient is refractory to conventional therapy or cannot 
undergo Haematopoietic Stem Cell Transplant (HSCT), 
infection is inevitable. Recovery from neutropenia is 
directly related to survival, and supportive care has a 
vital role in a state of neutropenia. Bacterial infections 
in neutropenic patients can be rapidly fatal. Invasive 
aspergillosis is the most common and serious fungal 
infection with a mortality rate of 80-90%.10 Suspicion 
of infection should lead to immediate institution of 
broad spectrum parenteral antibiotics. If fever persists, 
antifungal agents should also be added. 
Bleeding from thrombocytopenia is also life threatening. 
Some patients can tolerate low platelet counts with 
very few serious symptoms. There is no evidence that 
a prophylactic programme of regular transfusions is 
superior to transfusion for symptoms. Haemoglobin 
concentration should be maintained to allow full activity. 
Transfusion policy must be carefully considered in 
order to avoid sensitisation to transplantation antigens 
and transmission of viral diseases. A multidisciplinary 
approach should be taken when caring for this specific 
group of patients. Further epidemiological research will 
help to elucidate the current patterns and characteristics 
of infections in AA patients.11
(2) Androgens and Corticosteroids  
Historically androgens, or anabolic steroids, were 
the first specific form of therapy used in aplastic 
anaemia. They have a temporary benefit in the initial 
management. Androgen response and even dependence 
are observed but have not improved survival in any 
controlled trial.12 In some cases, they can accelerate bone 
marrow recovery after treatment with Antilymphocyte 
Globulin (ALG).13  Androgens have recently been shown 
to increase telomerase activity in human CD34+ cells, 
which may explain their effects in some patients. 9
Corticosteroids in conventional doses may ameliorate 
the serum sickness of ALG therapy, but have little 
activity alone in the disease. The use of low dose 
corticosteroids to enhance vascular stability has little 
basis in either laboratory experiments or clinical 
experience. Again, the side effects of long term usage is 
the major concern.
(3) Haematopoietic Growth Factors 
The use of haematopoietic growth factors (HGFs) to 
support blood counts is of limited value in SAA as 
predicted by in vitro studies and measurement of 
endogenous serum levels of HGFs, which are markedly 
elevated. HGFs administered alone play no role in the 
treatment of SAA.14 Granulocyte colony-stimulating 
factor (G-CSF), Granulocyte-macrophage colony-
stimulating factor (GM-CSF) and Interleukin-3 can lead 
to an increased number of granulocytes in patients who 
still have sufficient committed precursor cells. In patients 
with total aplasia, there is usually no improvement. The 
prognosis and survival of SAA are not influenced by 
such therapy. However, G-CSF has been described in 
conjunction with ATG and Cyclosporin (CsA) as a first-
line treatment.15 In this study, the response to G-CSF 
appeared to have prognostic values. 
(4) Bone Marrow Transplantation   
For young patients, if an HLA-identical sibling donor is 
available, their prognosis is improved by an allogeneic 
bone marrow transplantation (BMT), with a long term 
survival rate of 60 - 90 percent.8, 16 The major drawback 
is less than 25% of the patients have donors available 
and the age limitation policy in most centres. However, 
the survival of unrelated donor transplants has almost 
doubled in the past decade for improved donor/recipient 
matching. The preparative regimen consists of high dose 
cyclophosphamide combined with ALG or ATG. Better 
survival and low morbidity in young patients make 
allogeneic BMT the treatment of choice for children and 
adolescents. The age effect has remained significant 
with survivals of about 50% for patients over the age 
of 40. The major cause of excess mortality is chronic 
graft-versus-host disease (GVHD).17 The European 
Group for Blood and Marrow Transplantation (EBMT) 
is exploring the use of lower dose of cyclophosphamide 
in combination with low dose fludarabine and ATG in 
patients older than 30 years of age. The initial results are 
encouraging for lowering the transplantation-related 
toxicity.18 
(5) Immunosuppressive Therapy 
Immunosuppressive therapy (IST) has proven to yield 
superior survivals when compared with supportive care. 
8 The combinations of ATG, or CsA and steroids improve 
the overall response rate.13,19 Up to 67 percent of the SAA 
patients receiving combination immunosuppressive 
treatment may respond within 3 months.15 Responses 
can be subdivided into complete (CR) and partial (PR): 
the former with nearly normal blood counts.15 Partial 
responses requires at least transfusion independence. 
The immunosuppressant is with immunoglobulin 
preparations purified from the plasma of animals 
immunised with children's thymocytes in the case of 
ATG and thoracic duct lymphocytes for ALG. Although 
relatively non-specific in their reactivity for human 
cells, ATG and ALG lyse human lymphocytes.20 Both 
horse ATG and rabbit ATG have been used successfully 
in patients with acquired AA.8 CsA is a more specific 
immunosuppressive agent which blocks T-cell 
proliferation and lymphocyte function. When combined 
with ATG or ALG, CsA intensifies immunosuppression 
and increases the haematological response rate to about 
70 %.21
The standard first-line immunosuppressive therapy 
is currently horse ATG plus CsA and second-line 
treatment is rabbit ATG plus CsA, although the latter 
has been successfully used as a first-line therapy.22 
Conclusions 
S A A  c a n  b e  t r e a t e d  e f f e c t i v e l y  w i t h  e i t h e r 
immunosuppressive therapy (IST) or Haematopoietic 
stem cell transplant (HSCT). IST can be readily 
administered but is not curative. It is recommended 
for older patients or younger patients who do not have 
an HLA-identical sibling donor. HSCT produces long-
lasting haematologic recovery but requires a suitable 
donor, large financial resources, and may cause 
long-lasting GVHD. Age remains a major predictor 
in deciding treatment strategy. The final important 
message is early diagnosis and prompt treatment that 
will improve the outcome.
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Table 1: Drugs associated with idiosyncratic acquired aplastic 
anaemia1
Class Example
Antibiotics Chloramphenicol   
Sulphonamides
Cotrimoxazole
Nitrofurantoin
Anti-malarials Quinacrine (atabrine)
Chloroquine
Anti-helminthics Mebendazole
Anti-inflammatory Phenylbutazone
Indomethacin
Sulindac
Diclofenac
Ibuprofen
Piroxicam
Anti-rheumatics Gold salts
D-penicillamine
Anti-thyroids Potassium perchlorate
Carbimazole
Methimazole
Methylthiouracil
Propylthiouracial
Psychotropic/antidepressants Phenothiazines
Mianserin
Remoxipride
Dothiepin
Anti-convulsants Carbamazepine
Phenytoin
Mesantoin
Ethosuximide
Anti-diabetics Tolbutamide
Carbutamide
Chlorpropamide
Carbonic anhydrase inhibitors Acetazolamide
Methazolamide
Miscellaneous Allopurinol
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Introduction 
Lung cancer, predominantly non-small cell carcinoma 
(NSCLC), has remained the top cancer killer in Hong 
Kong, with more than 4,000 new cases every year and 
the 5-year survival around 15% only. The poor prognosis 
is mainly due to rather late presentation with metastatic 
diseases in the majority and the propensity of occult 
distant metastases even for early resectable stages. 
Systemic platinum-based chemotherapy has been the 
cornerstone treatment for advanced diseases over the 
past two decades. Because of the non-specific killing of 
rapidly proliferating cells, systemic chemotherapy is 
notoriously associated with a wide spectrum of adverse 
effects, often limiting the use in elderly subjects with 
multiple co-morbidities and poor performance status. 
At the turn of the century, with better understanding 
of lung cancer biology, the concept of targeted therapy 
has emerged from bench to bedside, with more specific 
killing of cancer cells. The most promising targeted 
approaches include anti-angiogenesis, anti-epidermal 
growth factor receptor (EGFR), and more recently the 
inhibition of anaplastic lymphoma kinase (ALK). This 
review serves to highlight the important advances in 
targeted therapy for NSCLC.
Anti-angiogenesis 
In general, malignant tumours cannot grow beyond 
2mm in size without developing a vascular supply.1 
The process of neovascularisation also provides a 
channel for tumour cells to migrate to the systemic 
circulation and subsequent development of distant 
metastases. In fact, tumours remain dormant and 
unable to metastasise in the absence of a functional 
vascular supply.2,3 Angiogenesis, whether physiological 
or pathological, is controlled by the balance between 
proangiogenic and antiangiogenic factors.4 The most 
important proangiogenic factor involved in tumour 
angiogenesis is the vascular endothelial growth 
factor (VEGF), which has become the target for 
antiangiogenic therapy in NSCLC.5 The VEGF pathway 
can be inhibited by agents that target VEGF or VEGF 
receptors. In particular, bevacizumab is an anti-VEGF 
recombinant humanised monoclonal antibody, which 
contains the human immunoglobulin G1 framework 
(93%) and murine VEGF-binding complementarity-
determining regions (7%) blocking the binding of VEGF 
to its receptors and subsequent downstream biologic 
activities. A randomised phase II study of bevacizumab 
in combination with carboplatin and paclitaxel or same 
chemotherapy alone as first-line treatment in patients 
with stage IIIB or IV NSCLC has demonstrated superior 
response rate, time to progression and survival in 
the bevacizumab combination arm, with increased 
risk of life-threatening haemoptysis in squamous cell 
carcinoma.6
In view of these promising results, a recent randomised 
phase III study (E4599) was conducted comparing 
the combination of bevacizumab with chemotherapy 
(carboplatin and paclitaxel) versus chemotherapy alone 
in the treatment of advanced chemonaive non-squamous 
NSCLC.7 There was a statistically significant survival 
advantage that favoured the bevacizumab combination 
arm (median survival 12.3 months vs 10.3 months in 
bevacizumab vs chemotherapy alone arms, hazard ratio 
for death 0.79, p=0.003). The major reported toxicities 
in bevacizumab versus chemotherapy alone arms were 
grade 3/4 neutropenia (25.5% vs 16.8%), grade 3/4 
hypertension (7% vs 0.7%), grade 3/4 proteinuria (3.1% 
vs 0%) and grade 3/4 haemorrhage (4.4% vs 0.7%). Out of 
the 17 treatment-related deaths, 15 were in bevacizumab 
arm and 2 in chemotherapy alone arm, in which the 5 
deaths related to haemoptysis were exclusively from 
the bevacizumab arm. This is the first landmark study 
to demonstrate superiority in combination of targeted 
therapy and chemotherapy compared to chemotherapy 
alone (standard-of-care) in the first-line treatment of 
patients with advanced NSCLC. In addition, another 
similar study has been conducted with the combination 
of bevacizumab and gemcitabine and cisplatin in 
advanced NSCLC (AVAiL study), with favourable 
progression-free survival in the bevacizumab arm 
compared to chemotherapy alone arm.8
Anti -epidermal  Growth  Fac tor 
Receptor (EGFR)
With advancement in molecular research, it becomes 
logical to target specific and crucial pathways involved 
in carcinogenesis to achieve better control of tumour 
growth while minimising the detrimental effects on 
normal body tissues. This concept of molecularly 
targeted therapy has been best exemplified by the 
inhibition of EGFR pathway in the treatment of 
NSCLC. The EGFR forms part of the signalling 
pathway that regulates tumour cell proliferation, 
invasion, angiogenesis, metastasis, and apoptosis. Since 
overexpression of EGFR is commonly found in NSCLC, 
various novel agents that inhibit EGFR pathway have 
been developed for treatment of this neoplasm. Apart 
from the use of monoclonal antibody that targets the 
EGFR extracellular binding site, small molecules that 
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target the intracellular adenosine triphosphate (ATP) 
binding site of EGFR tyrosine kinase have been studied 
extensively. 
Gefitinib (or Iressa) was the first EGFR tyrosine kinase 
inhibitor (TKI) used in the treatment of advanced 
NSCLC. Previous large-scale phase III trials (INTACT 
1 and 2) failed to show clinical benefit by combining 
gefitinib with platinum-based chemotherapy in first-
line treatment of advanced NSCLC.9,10  It was based on 
two large phase II trials (IDEAL 1 and 2) of gefitinib 
monotherapy in previously treated patients with 
advanced NSCLC that it was approved as second-line 
treatment.11,12  From these trials, the objective response 
rate was up to 18% with encouraging median survival of 
7-8 months, without the inclusion of a placebo arm. The 
most common toxicities were skin rash and diarrhoea, 
with rare occurrence of interstitial pneumonitis. Later a 
randomised, placebo-controlled, phase III study (ISEL) 
was reported on gefitinib versus placebo in treatment 
of advanced NSCLC who were refractory or intolerant 
to chemotherapy.13  It was shown that gefitinib (250mg 
daily) was not associated with significant improvement 
in survival compared to placebo (median survival 5.6 
vs 5.1 months in gefitinib vs placebo), despite some 
benefits among never smokers and patients of Asian 
descent. The commonest toxicities were skin rash (37%) 
and diarrhoea (27%). On the other hand, a subsequent 
phase III study of gefitinib versus docetaxel as second-
line treatment for advanced NSCLC (INTEREST trial) 
suggested similar clinical efficacy between gefitinib and 
docetaxel. 
Erlotinib (or Tarceva) is a later developed EGFR TKI 
that has also been extensively studied in treatment 
of NSCLC. Similar to gefitinib, large-scale phase III 
trials (TALENT and TRIBUTE) showed no clinical 
benefit in adding erlotinib to standard platinum-based 
chemotherapy as first-line treatment of advanced 
NSCLC.14 A randomised, placebo-controlled, phase III 
trial of erlotinib versus placebo in treatment of advanced 
NSCLC after failure to previous chemotherapy was 
reported.15 The erlotinib treatment arm was found to 
be superior in response rate (8.9% vs 1%), progression-
free survival (2.2 vs 1.8 months) and overall survival 
(6.7 vs 4.7 months) compared to placebo arm. The 
more frequent adverse effects associated with erlotinib 
treatment were skin rash (76% vs 17%), anorexia (69% 
vs 56%), stomatitis (19% vs 3%), diarrhoea (55% vs 19%), 
ocular toxic effect (28% vs 9%) and infection (34% vs 
21%) compared to placebo.
From earlier studies of gefitinib and erlotinib in 
treatment of advanced NSCLC, several clinical and 
molecular predicting factors for response to treatment 
were identified.16 Specific mutations in the EGFR 
tyrosine kinase domain (exons 18-21) have been shown 
to be associated with treatment response, while other 
mutations might predict drug resistance. Interestingly, 
activating EGFR mutations that predict sensitivity 
to EGFR TKI are more prevalent among females, 
Asians, never smokers, and adenocarcinoma, in which 
these predictive clinico-epidemiological factors have 
previously served as the selection criteria for treatment. 
Undoubtedly, the more exciting development derives 
from the recent reports of several first-line clinical 
trials of EGFR TKI in NSCLC carrying activating EGFR 
mutations.17,18  The first of such landmark phase III 
clinical trial (IPASS study) was conducted to investigate 
the clinical efficacy of first-line gefitinib compared with 
standard chemotherapy (paclitaxel and carboplatin) in 
an epidemiologically enriched population of advanced 
NSCLC (adenocarcinoma, never-smokers or former 
light smokers, Asians).17 It was found that only around 
60% of tumours carried EGFR mutations, despite 
selection based on favourable clinico-epidemiological 
factors predicting response to EGFR TKI. Among the 
subgroup of tumours with activating EGFR mutations, 
gefitinib demonstrated superior objective response 
rate (71.2% vs 47.3%) and progression-free survival 
(hazard ratio 0.48, 95% CI 0.36-0.64) compared with 
standard chemotherapy. On the contrary, among 
tumours without EGFR mutations, gefitinib fared worse 
in terms of objective response rate (1.1% vs 23.5%) and 
progression-free survival (hazard ratio 2.85, 95% CI 
2.05-3.98) compared with standard chemotherapy. The 
findings were subsequently confirmed with a Japanese 
study comparing first-line gefitinib versus paclitaxel/
carboplatin in advanced adenocarcinomas of lung 
carrying EGFR mutations.18 Recently, the preliminary 
findings of a first-line study comparing erlotinib with 
standard chemotherapy (gemcitabine and carboplatin) 
in NSCLC with EGFR mutations (OPTIMA study) were 
also reported with very promising improvement in 
progression-free survival in the erlotinib arm. Based on 
these recent confirmatory data, the need for sufficient 
tumour tissues at diagnosis for EGFR mutation testing 
has been widely recognised and the first-line treatment 
with EGFR TKI in advanced NSCLC carrying activating 
EGFR mutations is now the standard-of-care.
Emerging Approaches of Targeted 
Therapy 
Very similar to the evolution of EGFR targeting 
approach, it has been recently found that a novel 
oncogene (anaplastic  lymphoma kinase (ALK) 
rearrangements, commonly EML4-ALK fusion) could 
account for lung carcinogenesis in around 5%.19 
Interestingly, the occurrence of ALK rearrangements 
is particularly more prevalent among those with 
high chances of EGFR mutations (i.e. never-smokers, 
adenocarcinoma) and yet confirmed to be EGFR wild-
type (i.e. lack of mutations). A recent phase I study 
has provided very promising evidence that a specific 
ALK inhibitor (Crizotinib) could result in significant 
tumour response among those NSCLC carrying the 
ALK rearrangements.20 Ongoing phase II and III clinical 
trials on Crizotinib are underway to establish its role in 
management of this subgroup of NSCLC.
As the majority of advanced NSCLC would progress 
shortly after  completion of  f irst- l ine systemic 
chemotherapy, the role of EGFR TKI as a maintenance 
treatment has recently been investigated and shown 
to offer survival benefits than the conventional 
approach (i.e. observation after completion of first-
line chemotherapy).21 Since EGFR TKI is mostly well-
tolerated even for years, this approach of maintenance 
treatment is considered a feasible treatment option after 
standard first-line systemic chemotherapy.
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Conclusions 
The era of targeted approach in the management of 
advanced NSCLC has certainly begun over the past few 
years and the field is expected to be evolving rapidly 
in the near future. Lung cancer is no longer considered 
a homogeneous disease. Despite the traditional 
classification based on histology, there is increasing 
clinical demand of tumour molecular profiling to allow 
logical choice of specific targeted treatment. Second-
generation targeted agents and multi-targeted agents 
are currently tested in clinical trials, which will help to 
expand the existing armamentaria in the battle against 
lung cancers.  
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Introduction
With research and development, there have been 
increasing advances in the field of oncology, leading to 
better outcome of all cancer patients. Recommendation 
of systemic adjuvant therapy and choice of optimal 
agents for early-stage breast cancers remain a challenge.
Breast cancer has been the most common female cancer 
worldwide and is still the most common female cancer 
in Hong Kong with 1 in 21 cumulative life-time risk1-2. It 
is indeed a major public health concern. The incidence 
of breast cancer is increasing. 
Thanks to our scientists and dedicated oncologists who 
have made great successes in translational research, as 
breast cancer patients of all types and all stages are now 
living longer with much better quality of life, especially 
those with metastatic disease. While breast cancer 
patients are managed in a personalised manner in the 
context of the new evolving breast cancer molecular 
classification, the rapid development of all new cancer 
treatments has put a new challenge everyday for the 
physicians who are caring for cancer patients in terms 
of the high expectation of the patients and the general 
public and the relatively high costs of the new targeted 
therapy and prognostic tests. This requires the most 
optimal communication skills to discuss openly about 
different treatment options available with the patients. 
This article aims at giving an update of personalised 
management of breast cancer with particular references 
to adjuvant therapy and the challenges ahead with this 
new approach of practice.
Overview of Major Breakthroughs – 
Higher Hopes?
From Conventional Adjuvant Regimen to Newer 
Generations
Adjuvant therapy after definitive surgical resection 
of the breast tumour has been shown to increase the 
overall outcome of high-risk breast cancer patients, 
in terms of prevention of local recurrence and distant 
metastasis1. For example, adjuvant radiotherapy is 
given according to the tumour risk to help prevent local 
recurrence while the benefits of adjuvant chemotherapy 
has become the standard of care for selected high-
risk patients since the data published more than 30 
years ago by Bonadonna3. Since then, there have been 
many more international clinical trials showing further 
benefits with different chemotherapy regimens, such as 
the anthracycline-based chemotherapy was associated 
with further risk reduction when compared with the 
conventional cyclophosphamide, methotrexate and 
fluorouracil (CMF) regimen1; followed by the added 
value of taxanes (T: paclitaexel, docetaxel) being 
included in many newer third generation regimens 
(ACx4 followed by Tx4) in the 1990s4. The BCIRG 001 
trial further showed 6 cycles of taxotere, anthracycline 
and cyclophosphamide (TAC) was superior to 6 cycles 
of fluorouracil, anthracycline and cyclophosphamide 
(FAC), but the TAC regimen was indeed associated with 
more significant myelosuppression including grade 4 
neutropenia and even febrile neutropenia5. The recent 
US Oncology Research Network trial has suggested 
superiority of replacing anthracycline (doxorubicin) with 
taxanes (taxotere) (i.e. TC replacing AC) 6. Up till now, 
there is indeed no recipe for adjuvant chemotherapy as 
individual assessment of all prognostic and predictive 
factors are all taken into account while open discussion 
with patients and the carers is of paramount importance 
before any final treatment decision could be made.
From Risk Assessment to Target Determinant
In the past, the final histopathology report of the 
definitive surgery for breast cancer has been crucial 
in terms of the decision on indication of adjuvant 
chemotherapy. Clinico-pathological features such as 
young age at presentation, pathological tumour size 
of more than 2 cm, high grade of tumour, presence of 
peritumoural vascular invasion, positive axillary lymph 
nodes, hormone-negative tumours and over-expression 
or amplification of the HER2/neu gene have been the 
indications for adjuvant chemotherapy7. However, 
with our better understanding of new pathways and 
breast cancer molecular biology, and the advent of 
trastuzumab which has now become the standard of 
care for HER-2 over-expressed disease as supported 
by the pivotal trial of the HERA trial, showing an 8.4% 
absolute benefit in disease-free survival after a total of 
1-year adjuvant trastuzumab8, the “target” of the breast 
tumour has become the main determinant for adjuvant 
therapy decision. With the added value of aromatase 
inhibitors in terms of adjuvant hormonal therapy for 
the post-menopausal hormone receptor positive breast 
cancer patients, the hormone receptors (oestrogen 
receptor and progesterone receptor) and the HER-
2 receptor status have become important predictive 
factors of treatment response.
Therefore, there is a shift of paradigm of management 
and decision making on the most optimal adjuvant 
management for breast cancer patients, from the 
analysis of just the clinico-pathological features of the 
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breast tumour to the taking into account of predictive 
factors for treatment response and also potential 
prognostic indicators. This has further led to our better 
understanding of all the primary breast cancers in 
the context of different molecular subtypes. In the old 
days, systemic adjuvant therapy was indicated on the 
assumption of existing residual microscopic disease, 
with estimation of risk based entirely on extrapolation 
of data from previous clinical trials. It was further 
assumed that biological characteristics and treatment 
responsiveness are consistent between micrometastases 
and the primary tumour. 
From “One-Size-Fits All” Approach to Tailored 
Made Management
Breast cancer is a heterogeneous disease. Molecular 
profiling identifies at least five breast cancer subtypes: 
luminal-A, luminal-B, HER2-enriched, basal-like and 
normal breast-like9. An immunohistochemical profile 
based on the degree of expression of oestrogen receptor 
(ER), progesterone receptor (PgR), HER-2 and Ki-67 
similarly identifies breast cancer subtypes which have 
diverse disease biology, behaviours, relapse risks and 
treatment responses10. Though current evidence-based 
adjuvant treatment options include chemotherapy, 
endocrine therapy and anti-HER-2 targeted therapy, 
there is still an observational phenomenon where 
individuals at low risks who develop disease recurrence 
despite standard systemic treatment while some 
patients with high-risk disease remain relapse free for a 
long time without adjuvant intervention. On the other 
hand, promising novel agents that are being explored 
include therapies that target angiogenesis, DNA damage 
repair, apoptosis and immunity; but the evidence for the 
efficacy of these agents is lacking in the adjuvant setting. 
Therefore, the recommendation of the most appropriate 
adjuvant therapy for an individual diagnosed with 
early-stage breast cancer remains a difficult task11. The 
more we know, the more we know how much we do 
not know. With the “one-size-fits all approach” being 
over in the management of breast cancer patients, there 
has been introduction of various decision making tools 
such as different multi-gene signatures to better tailor 
our management plan for individual patients.
Breast Cancer Assessment Tools
As decisions about adjuvant therapy must be made on 
an individual basis while there is no recipe for adjuvant 
therapy for breast cancer patients, there comes various 
prognostic and predictive assessment tools with the 
aim to assist breast oncologists to decide on the most 
appropriate treatment for each breast cancer patients, 
namely the computer-based model, Adjuvant! Online, 
international guidelines and consensus and other 
models using multi-gene signatures.
Adjuvant! Online
This is a validated computer-based model (https://www.
adjuvantonline.com) which has been a popular breast 
cancer assessment tool among most breast oncologists 
giving an approximate risk evaluation in terms of 10-
year breast cancer outcome based on selected prognostic 
features. This prognostic model was created using 
10-year overall survival data from the Surveillance, 
Epidemiology, and End-Results (SEER) registry data for 
women aged between 36 and 69 years diagnosed with 
unilateral, unicentric, invasive breast adenocarcinoma 
between 1988 and 199212. However, this prognostic 
tool is limited as it does not incorporate important 
prognostic factors such as oestrogen receptor (ER), 
progesterone receptor (PgR), HER-2 receptor status 
or any proliferative markers such as Ki-67 level. The 
potential benefits of using third-line chemotherapy 
may sometimes be over-estimated, especially in those 
early-stage disease when available data are being 
extrapolated13.
International Guidelines and Consensus
The St. Gallen Consensus which is one of the major 
international guidelines with regard to the most 
appropriate breast cancer adjuvant management 
with revision made every two-yearly at the St. Gallen 
Breast Cancer Conference during March every other 
year, has incorporated both risk assessment and 
therapy recommendation in its latest version in 2009. 
It has incorporated the standard cut-off levels for ER, 
PgR, HER-2 and Ki-6714. The consensus recommends 
that tumours with ER staining ≥1% are classified as 
hormone receptor positive15. The St Gallen Consensus 
recommends that patients with small primary tumours 
(pT1aN0) with no vascular invasion may be spared 
chemotherapy. Patients with triple-negative (ER 
negative, PgR negative and HER-2 negative) tumours, 
have no systemic alternatives to chemotherapy.  For 
patients with HER2-positive tumours, chemotherapy 
is indicated with anti-HER-2 targeted therapy with 
a total of 1-year adjuvant trastuzumab. For HER2-
positive, small (<1 cm) node-negative tumours, the St 
Gallen Panel acknowledged emerging evidence of poor 
prognosis despite small tumour size. However, the lack 
of robust prospective evidence did not allow a definitive 
recommendation regarding anti-HER2 therapy in this 
cohort at this moment.
Multi-gene Signatures Assessment Tools
Over the last few years, significant effort has been made 
in identifying relevant molecular markers as prognostic 
and predictive factors to aid better decision making on 
adjuvant therapy for breast cancer patients. The innate 
capacity of a tumour to metastasise has prompted the 
use of multi-gene profiling for relapse risk estimation. 
A potential limitation of these mRNA-based signatures 
is the assumption that measurable mRNA will be 
translated to protein. However, most mRNA is not 
translated. Some markers, such as HER2, have evidence 
of a strong correlation between gene amplification and 
protein over-expression. 
The 21-gene Oncotype DX® (Genomic Health Inc., 
Redwood City, CA) assay was developed to assign 
adjuvant chemotherapy in women with ER-positive, 
node-negative breast cancers who would receive 
adjuvant endocrine therapy. Sixteen cancer genes and 
five reference genes are used to calculate a Recurrence 
Score (RS) between 0 and 100, which correlates to a 
specific likelihood of recurrence within 10 years of 
diagnosis, defined as low (RS <18), intermediate (RS 
18–31) or high (RS >31). As a prognostic tool for ER-
positive, node-negative women, Oncotype DX® is 
superior to patient age, tumour size or tumour grade, 
and to a modified 5-year outcome version of Adjuvant! 
Online16. However it remains to be seen whether 
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Oncotype DX® is more useful than combined assessment 
of ER, PgR, HER2 and Ki-67 at a high-quality laboratory. 
In another study, Microarray in Node-negative Disease 
may Avoid Chemotherapy Trial (MINDACT), the 
genomic profiling of a 70-gene signature (MammaPrint®) 
is studied and compared with the conventional clinical 
assessment to determine the indication of chemotherapy 
in women with node-negative breast cancers. So far, 
studies on the MammaPrint® 70-gene signature have 
shown that the multi-gene signatures correlate a good-
risk signature with chemoresistance and a poor-risk 
signature with increased chemosensitivity, but they do 
not show that MammaPrint® is more clinically valuable 
than morphology and immunohistochemical (IHC) 
subtyping in predicting these responses.
What Next After All High Hopes – 
More Burden?
Matching Science with the Affordability
Our research and development has proven success 
as evidenced by the promising results of the clinical 
trials, leading to the many more options and avenues 
in the treatment for breast cancer patients. While the 
incidence of breast cancers is increasing and the number 
of breast cancer patients living with the disease is also 
increasing, the access to all the new regimens especially 
the targeted therapy and the assessment tools is not 
equal to all individuals. Currently, the use of adjuvant 
trastuzumab in the public sector is a self-financed 
item for patients in Hong Kong, so are some of the 
taxanes in the intermediate risk group. The cost of the 
Oncotype Dx is indeed a self-financed item if the patient 
and physician would like to ascertain the benefits of 
chemotherapy for the node-negative hormone receptor 
positive early breast cancer patients. The current cost 
of a total of 1-year adjuvant trastuzumab is about HK$ 
200,000 while the cost of the Oncotype Dx test is about 
HK$ 20,000. The cost-effectiveness of the Oncotype Dx 
assay has been verified in the United States but not in 
individual countries and thus there is another challenge 
of whether the clinical data derived from these multi-
gene signature assays could be translated into direct 
application in other non-US countries such as the Asian 
population like our Chinese population.
Open Discussion and Communication is of 
Paramount Importance
With the ever increasing number of new anti-cancer 
treatments and molecular assays, there comes the 
increasing high expectation from the patients and 
their families. While the issue of life and death, 
breaking bad news and dealing with complex psycho-
oncology of cancer patients is usually not thoroughly 
touched during our traditional medical training, not all 
oncologists or cancer physicians are well equipped with 
the proper communication skills in terms of discussing 
various costs and options of anti-cancer treatments with 
the breast cancer patients. This has been supported by 
the recent cross-sectional study looking at the perceived 
difficulties and stress from a cancer patient consultation 
among 134 Australian cancer specialists, all being 
members of the Clinical Oncological Society of Australia, 
and it has shown that to the doctors, the most stressful 
practice being discussing the high-cost drugs during 
the consultation17. There is indeed a growing challenge 
among the oncologists in discussing all the high-cost 
treatment options with the cancer patients18. Therefore, 
there is an unmet need to further better equip our cancer 
physicians and cancer carers with better communication 
skills so that they could provide relevant information 
with regard to the high-cost treatment and relevant tests 
to our cancer patients.
Conclusion
There has been ever increasing hopes for breast cancer 
patients with our better understanding of the breast 
cancer molecular biology, and the ever increasing 
avenues of different treatment options for different 
subtypes of patients. The “one-size-fits-all” approach is 
over and we have come to the new era of personalised 
medicine for our breast cancer patients. However, 
whether higher hopes mean greater burden in terms 
of the extra time and empathy to discuss various 
treatment options including the ever growing list of self-
financed items with our patients, and whether we could 
directly translate all the clinical data from the western 
population to our own clinical practice, this requires the 
continuous effort of the multidisciplinary approach for 
breast cancer management, and further international 
multi-centre trials and investigation of biological and 
treatment heterogeneity within breast cancer subtypes, 
such as good prognosis subsets within triple-negative 
disease or benefit of anti-HER2 therapy in small, HER2-
positive tumours, and within individuals are warranted 
to further advance our risk assessment. While we are 
planning to explore further clinical utility of promising 
assessment tools in future and biologically driven 
trials, we should also better equip our oncologists or 
oncologists-to-be with better communication skills 
which involves an appreciation of both Art and Science. 
There is no single recipe for adjuvant management of 
breast cancer patients, but there should always be an 
open discussion with the patient, the family and all 
other supporting parties before any treatment decision 
is made.
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Introduction
Hepatocellular cancer (HCC) is the sixth- and eleventh-
most common cancer worldwide in men and women 
respectively.1 It occurs most often in male patients 
over 40 years of age.  It is the most common primary 
liver malignancy, with an annual incidence of over 
500,000 new patients worldwide with more than half of 
the new cases occurring in China.2 In the Asia-Pacific 
region, HCC is the third most common cancer and the 
second most common cause of cancer-related death. 
The incidence rate for HCC in the Asia-Pacific region 
has been rising, linked to a high hepatitis infection rate. 
On the other hand, the incidence of HCC in Western 
countries is rising due to the sequels of hepatitis C 
infection and alcoholic cirrhosis. In the United States, the 
incidence of HCC almost doubled during the last two 
decades.3,4 There will be a steady rise in the incidence of 
HCC worldwide due to an increasing prevalence of non-
alcoholic steatohepatitis associated with the metabolic 
syndrome. It becomes one of the important global health 
problems that physicians have to face, especially in the 
Asia-Pacific region.
HCC is a cancer of high particular relevance in Hong 
Kong because of the high prevalence (10%) of hepatitis B 
infection. It is the second most common cancer causing 
death in Hong Kong.5 Current effective treatments for 
HCC include liver resection, transplantation, various 
local ablative and trans-arterial therapies. Nevertheless, 
only around 20% of patients, mostly diagnosed by 
regular screening, may benefit from these potentially 
curative surgical therapies. The majority of patients have 
unresectable HCCs because of advanced tumour stage 
and poor liver function.6,7 Besides, transplantation is 
indicated only for early small HCCs, and its application 
is limited by the shortage of liver graft, which is a 
particularly severe problem in Hong Kong.8
Prior to the advent of targeted therapy in HCC, most 
advanced HCC patients were only palliated by various 
systemic therapies and in fact a significant proportion 
of patients were treated by at best supportive care 
only.9 Historically, the prognosis of the advanced 
HCCs was dismal with an overall survival of 2.3-2.6 
months.10 HCC is a relatively chemo-resistant tumour 
and is highly refractory to cytotoxic chemotherapy. 
There is no convincing evidence so far that systemic 
chemotherapy improves overall survival in advanced 
HCC patients.11 Single-agent doxorubicin has been 
shown to produce a response rate of about 10–15% 
but with no proven survival benefits.12 Nevertheless, 
significant grade 3 or 4 toxicities, especially neutropenia, 
are encountered in patients treated with doxorubicin.13 
The newer generation of chemotherapeutic agents, 
such as gemcitabine,  irinotecan and pegylated 
liposomal doxorubicin, also shows disappointing 
results.14,15 The combination of cisplatin, interferon-
alpha-2b, doxorubicin and fluorouracil (PIAF) caused 
a great deal of enthusiasm at one time.  However, in 
the phase III study, although this combination had 
achieved seemingly higher response rates than other 
combinations, there was no demonstrable survival 
benefits and there were considerable toxicities.16 
Emerging insights into the biology and molecular 
signalling pathways in cancer cells has led to the 
identification of potential targets for intervention 
and the advent of promising targeted therapy for the 
treatment of otherwise chemo-resistant tumours. In 
contrast to other solid tumours, HCC has a complex 
molecular and genetic pathogenesis. Chronic liver 
injuries, due to either viral infections or environmental 
toxins play a pivotal role in the carcinogenesis.  Many 
key carcinogenic pathways play a pivotal role in the 
development of HCCs, and it is difficult to assess which 
is the driven pathway for hepato-carcinogenesis.17 
Among these targets, exciting clinical results have been 
shown by targeting the anti-angiogenic pathway and 
the Raf/mitogen-activated protein kinase-extracellular 
signal-regulated kinase (MAPK)/extracellular signal-
regulated kinase (ERK) pathways.  Other signalling 
pathways such as epidermal growth factor receptor-1 
(EGFR), and phosphatidylinositol-3-kinase (PI3K)/AKT/
mammalian target of rapamycin (mTOR) have also 
emerged as attractive avenues for future therapeutic 
interventions. Notably, thus far, most of these targets 
mainly focus on targeting the tumour growth pathway 
and/or inhibiting tumour angiogenesis.
Sorafenib (Bayer 43-9006; Nexavar) is an oral multi-
kinase inhibitor that blocks tumour proliferation by 
targeting the Raf/MAPK/ERK signalling pathway; it 
also has significant anti-angiogenic properties attained 
by targeting the tyrosine kinase VEGR-2, VEGFR-3 
and PDGF receptor β.18 Recently, two pivotal phase 3 
randomised placebo-controlled trials in the West19 and 
Asia-Pacific region20 have clearly shown the survival 
benefits in using single agent sorafenib in treating 
patients with advanced HCC: In the SHARP study, 
602 patients with biopsy-proven advanced HCC who 
had not received any prior systemic treatment were 
evaluated and randomised to receive either sorafenib 
(400 mg twice daily, n = 299) or a placebo (n = 303). 
Of note in this study, only patients with Child-Pugh 
A cirrhosis were included, and 37 (6%) and 56 (9%) 
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of patients were hepatitis B and hepatitis C carriers, 
respectively.  The results demonstrated a significant 
improvement in both OS (median 10.7 versus 7.9 
months) and TTP (median 5.5 versus 2.8 months) in 
the sorafenib group versus the placebo group.  These 
results indeed represented a 44% increase in OS (hazards 
ratio, 0.69; p = 0.00058) and 73% prolongation in the 
TTP (hazards ratio, 0.58; p = 0.000007) Sorafenib was 
generally well-tolerated and serious adverse events 
only occurred in 13% of patients.  Similarly,  an Oriental 
sorafenib study was performed to investigate the 
efficacy and tolerability of using single agent sorafenib 
in treating advanced HCC patients in hepatitis-B 
endemic Asian populations.21 In this study, a total of 226 
patients were recruited and randomised in a 2:1 fashion, 
i.e. 150 patients on sorafenib and 76 patients on placebo. 
The disease control rate was 35% in the sorafenib arm. 
The median OS of patients on sorafenib was 6.2 months 
which was significantly better than 4.1 months achieved 
in patients on placebo (p=0.0155).  Based on the results of 
these two pivotal trials, sorafenib has been approved by 
the U.S. Food and Drug Administration (FDA) and other 
regulatory authorities worldwide for the management 
of advanced HCC patients.   Although these two pivotal 
studies have demonstrated good activity and tolerability 
in treating advanced HCC patients with sorafenib, 
most of the enrolled patients belonged to Child-Pugh A 
cirrhosis with favourable clinical parameters.  Therefore, 
the benefits and safety profile of sorafenib in unselected 
advanced HCC patients, especially those with Child-
Pugh B/C patients or other poor prognostic factors are 
still unknown.  More mature results are needed before 
recommending the routine use of sorafenib use in Child-
Pugh B patients.     
 
The recent development of sorafenib represents a step 
forward in the treatment of advanced HCCs.  However, 
it is just the beginning of a new horizon in molecular 
targeted therapy of HCC.  It has promulgated strong 
interests among researchers to unravel more underlying 
molecular mechanisms of HCC growth and metastasis. 
Besides sorafenib, other targeting agents have also 
shown encouraging activity in the treatment of patients 
with advanced HCC in early clinical trials.  
 
HCC is a highly vascular tumour with a high propensity 
for vascular invasion, and thus tumour angiogenesis 
plays a pivotal role in the pathogenesis of HCC.22,23 
Vascular endothelial growth factor (VEGF)23 is the 
most potent known angiogenic factor and its over-
expression varies from 37% to 100% in HCC cells, 
and aberrant VEGF expression is a prominent feature 
in HCC.24 The anti-angiogenic effect can be achieved 
either by using monoclonal antibodies to target the 
VEGF or employing anti-angiogenesis inhibitor to 
block various VEGF receptors.  Bevacizumab as a 
single agent or in combination with other agents has 
shown modest activity in treating advanced HCCs. 
In the study conducted by Siegel et al., among 46 
enrolled patients with advanced unresectable HCC, 
single agent bevacizumab achieved a 13% response 
rate (RR), while 65% of patients had stable disease 
(SD)25. Nonetheless, 4% of the enrolled patients had 
arterial thrombosis and grade 3 or higher haemorrhage 
occurred in 11% of patients, including one patient who 
died of variceal bleeding. On the other hand, Thomas et 
al. had performed a non-randomised phase II study of 
combination of high dose bevacizumab with erlotinib in 
the treatment of advanced HCC patients.  Based on the 
results of the enrolled patients, the RR was surprisingly 
high with one patient having complete response, 22% 
PR and 55% having SD.26 Moreover, the OS was 15.65 
months.  Nevertheless, a significant proportion of the 
enrolled patients discontinued from the study due to 
treatment-related toxicities and one patient even died 
from treatment-related adverse events. Sunitinib is 
another oral anti-angiogenic multi-targeted tyrosine 
kinase inhibitor with partially overlapping target 
inhibition with sorafenib.  It inhibits VEGF receptor 
1-3, PDGFR-α and β, c-kit, Flt-3, colony-stimulating 
factor receptor type 1 and RET kinases.27 Although 
phase II studies employing different doses of sunitinib 
suggested initial activity of single-agent sunitinib in 
treating advanced HCCs28, a recent randomised phase 
III sunitinib study was halted early because of concerns 
about efficacy and treatment-related toxicities. Thus, 
targeted agents with comparable kinase profiles may 
produce very different clinical outcomes in similar 
patient populations.  Brivanib (BMS-582664) is a small 
molecule tyrosine kinase inhibitor of both VEGF and 
fibroblast growth factor(FGF) receptor family.   Raoul 
et al.29 reported the results of an open-label phase II 
study on the use of brivanib both as first-line treatment 
of advanced HCC patients.  In this study, when 
brivanib was used as first-line treatment of 55 advanced 
HCC patients, the overall RR was 5%, while another 
47% of the patients achieved SD. The TTP was 2.8 
months.  Currently, brivanib as a single agent is being 
investigated in large-scale phase III randomised studies 
either as first-line therapy compared with sorafenib 
or as second-line treatment after sorafenib failure for 
advanced HCC patients.  Last but not least, linifanib 
(ABT-869) is another novel orally active, potent and 
selective inhibitor of the VEGF and PDGF families of 
receptor tyrosine kinases.  Toh et al recently reported 
the results of a phase 2 trial of ABT-869 in advanced 
HCC.30 In this open-label, multicentre phase II trial, 
oral ABT-869 was administrated in patients with both 
Child Pugh A and B cirrhosis. The median OS of the 
enrolled patients was approaching one year.  Based on 
this preliminary results, a randomised phase III trial is 
underway to assess the efficacy and tolerability of ABT-
869 compared with sorafenib as first line treatment for 
patients with advanced HCC.
While sorafenib and other anti-angiogenic multi-
targeted tyrosine kinase inhibitors show early promises 
in the management of advanced HCC patients, most 
of these targeted agents have demonstrated very low 
response rate when they are used alone.  They will 
not induce radiological regression of the tumour but 
rather result in mostly disease stabilisation.  Thus, the 
other direction in the future systemic trials of treatment 
of advanced HCCs is to test the potential benefits of 
combining sorafenib together with various systemic 
agents to increase the response rate and downstage the 
tumour for potential curative resection.  By adding other 
systemic agents to sorafenib, there is a potential for 
gaining additional efficacy through possible synergistic 
effects.  To this end, several investigators are trying to 
investigate the benefits of adding either novel molecular 
targeting agents, biological agents or chemotherapeutic 
agents to enhance sorafenib efficacy.  In particular, 
there are preliminary data in the literature suggesting 
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potential benefits in combining sorafenib with various 
chemotherapy agents to enhance sorafenib activity. 
The results from a randomised phase II study by Abou-
Alfa et al. showed encouraging activities in combining 
sorafenib with doxorubicin in the treatment of advanced 
HCC patients.31 This study has suggested possible 
synergistic actions between sorafenib and doxorubicin 
as sorafenib may potentially inhibit the Ras/Raf/MEK/
ERK pathway, which in turn may prevent activation 
of the multidrug resistance pathway.32 Notably, more 
than one-third of the recruited patients experienced 
significant treatment related toxicities, such as febrile 
neutropenia and treatment-related death.  Instead of 
using doxorubicin as the chemotherapy partner, our 
group at Queen Hospital, the University of Hong Kong 
has reported the results of a multi-centre phase II study 
of combining sorafenib with capecitabine and oxaliplatin 
(SECOX) in the treatment of advanced HCC patients.33 
Our results demonstrated promising activities with an 
overall RR of 16% and OS 11.8 months.  Moreover, this 
regimen was well-tolerated by most enrolled patients. In 
view of this promising result, a large scale randomised 
phase III Asia-Pacific study is underway to investigate 
the benefits of this regime over single agent sorafenib 
in the treatment of advanced HCC patients.  Clinical 
trials of combination of sorafenib with various other 
chemotherapeutic agents, such as fluoropyrimidine, 
platinum compounds and gemcitabine are still in the 
stage of active patient recruitment and the results will 
be eagerly awaited.
 
Conclusion
In summary, in the era of targeted therapy, there are 
some real progresses made in the systemic treatment 
for advanced HCC patients. The recent development 
of single agent sorafenib in the treatment of advanced 
HCC patients indeed represents a major milestone in 
the treatment of advanced HCC. It proves the concept 
that molecular targeted therapies, especially anti-
angiogenic agents, play a pivotal role in the treatment 
of HCC. Nevertheless, our current understanding of the 
underlying pathogenesis of HCC is still very primitive. 
More in-depth basic and translational researches need 
to be done to further elucidate the underlying molecular 
pathogenesis in the disease. The future direction in 
improving the survival of advanced HCC patients will 
likely rely on either  combining sorafenib with others to 
circumvent the complex signalling pathways in HCC or 
the development of novel targeted agents which can target 
the main oncogeneic driving pathway in the disease.
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Introduction
It has been estimated that there would be 148,000 new 
cases of colorectal cancers in 2008, about 2/3 from 
the colon and 1/3 from the rectum. The annual death 
figure from colorectal cancers was estimated to be 
50000 in 2008(data taken from American Cancer Society 
statistics). This discrepancy can be explained by the 5 
year localised survival rate of 90% and 5 year overall 
survival rate of 64% according to the latest statistics 
from the American Cancer Society. The push for early 
detection efforts made in the past decade leading to 
earlier detection of limited stage colorectal cancers and 
the improvements made in therapeutics in metastatic 
colon cancers are responsible for these progresses. 
Due to the different approaches to the management of 
resected colon cancers and the current debate in how 
to best manage limited stage rectal cancers where pre-
operative chemo-radiation may be the optimal approach 
for limited stage rectal disease, this article will focus on 
reviewing the current approaches to adjuvant therapy 
for resected limited stage colon cancers (LSCC) only.
Fig 1 Survival of Resected colon cancers according to stage. AJCC 
6th edition
Staging of Colon Cancer
Currently the AJCC recommends the TNM staging 
system. It is based on tumour size and pathology, 
lymph nodes status and the extent of metastases. LSCC 
encompasses tumours that have not spread beyond 
draining regional LNs at pathological staging. The disease 
survival of colorectal cancers broken down by stages is 
summarised in Fig 1 using the recently superseded AJCC 
6th edition. LSCC encompasses disease from Stage I to 
Stage III. Within Stage III disease, increasing number of 
positive LNs is no doubt related to worsening outcome 
after surgery. In fact with positive LN numbers above 15 
the outcome is comparable to Stage IV disease. The focus 
of this paper will be on Stage I to III disease.
Development of Adjuvant 
Chemotherapy for Colon Cancer
In the era of modern imaging techniques, all patients 
should be evaluated with CT or CT/PET scans prior to 
curative intent surgery after the diagnosis of colorectal 
cancer is made. If there is no distant metastasis detected 
by the chosen imaging modality, a curative procedure 
is performed. After surgery, treatment failure can 
be either local recurrence or the development of 
metastatic disease at distant organs. A third scenario 
is the development of new primary tumours which in 
general occur some years after the initial diagnosis. 
Local or peritoneal disease relapse may be attributed 
to suboptimal resection or seeding during the primary 
operation. If such events are suspected, radiation can 
offer excellent local disease control. New primary 
tumours that occur independently of the previous 
disease on the other hand are revealed through diligent 
surveillance of the remaining colon with regular 
examinations.
The presence of micro-metastatic tumour cells which are 
too small to be demonstrated by conventional imaging 
techniques prior to surgery is the cause of the most 
fatal form of recurrence. Distant metastases represent 
outgrowths of such disseminated cells and in general 
the treatment is palliative since the patient can no longer 
be cured.
We have information back in the 1990s that adjuvant 
chemotherapy with 5FU based regimens following 
curative intent surgery for colon cancers can deliver 
survival benefits.1 However it was also noted that 
clinical benefits from adjuvant chemotherapy for limited 
stage (II and III) colon cancers can disappear with 
increasing clinical follow-ups.2
Current Adjuvant Therapy 
Recommendations for LSCC
Within LSCCs, the probability of survival is heavily 
influenced by the amount and degree of involvement 
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of the cancer beyond the primary organ. It varies from 
the excellent prognosis of 90+ % survival of a Stage I 
disease at 5 years to a worrisome less than 50% survival 
at 5 years for Stage IIIC disease. Staging is a powerful 
surrogate for the likelihood of tumour dissemination. 
Since the target of adjuvant therapy is beyond our 
clinical detection limit, we use the degree of tumour 
spread as our guide in identifying patients at risk of 
disease relapse.
Due to the excellent outlook for resected Stage I 
patients, there is no adjuvant therapy recommended 
for this group of patients. There is a paucity of data 
investigating the role of adjuvant therapy in Stage II 
colon cancers alone despite the relatively poor outcome 
in the subgroup of Stage IIB patients. The one study 
which recruited an overwhelming number of Stage II 
patients was the QUASAR study. Whilst there was a 
statistically significant improvement in outcome, the 
difference was small and achieved with considerable 
mortality. Therefore, current literature does not support 
the routine use of adjuvant therapy for early stage 
colorectal cancers (Stage I and II)3-5. 
In the review of CRC adjuvant therapy by de Gramont 
and Haller5, the current therapeutic standard for 
resected Stage III disease is oxaliplatin based regimen 
FOLFOX 4 or FLOX for 6 months where the absolute 
improvement in DFS is approximately 7% according 
to the most recent reports from the MOSAIC trial and 
NSABP C-07 when compared to the older standard of 
5FU/leucovorin9 with an overall total risk reduction of 
more than 25% over observation alone. 
One should also bear in mind that in the landmark 
studies which showed advantages of using oxaliplatin 
based adjuvant therapy, there was a significant 
enrollment of Stage II patients, yet there was no benefit 
seen in a retrospective non-preplanned subset analysis6. 
An exploratory analysis of high risk Stage II patients 
did show a benefit of 7.7% for 5 yr DFS favouring those 
who received FOLFOX 46. It must also be noted that 
the trials presented were performed with the AJCC 
6th edition staging system. The obstacle to a definite 
answer has been the lack of reliable predictor of adverse 
outcome in early colorectal cancers. Whilst staging is 
useful, there is a clear need of better prognostic markers 
for disease relapse. Without such markers to distinguish 
the heterogeneity of Stage II disease, it is a mountainous 
challenge to design an adjuvant trial to address this 
sizable group of patients which is increasing due to 
the early detection of disease with the widely adapted 
practice of population screening. 
Past Limitations of TNM Staging of 
Colon Cancer
Currently the stage of disease at diagnosis is the best 
prognostic predictor for LSCCs. Although staging 
of colon cancers can provide excellent prognostic 
information for LSCC, careful inspection of Figure 2 
will reveal an anomaly of prognostic prediction of TNM 
staging. 5 year survival of Stage IIb disease is actually 
worse than Stage IIIa disease. Stage IIb is defined as T4 
disease but LN negative.
 
Fig 2 Survival of colorectal cancers broken down by stage according 
to AJCC 6th edition.  Adapted from21
Since staging is heavily dependent on the LN status, 
a nagging challenge is to define a standard for LN 
sampling for LSCCs. A consistent LN assessment 
standard is key to distinguish true Stage II disease and 
understaged Stage III. Recently multiple work groups 
have addressed this concern and although slightly 
different in regards, the minimum number of LNs 
sampled in staging of colorectal cancers is agreed to 
be at least 12 (NCCN guidelines, www.nccn.org) and 
10-14 in the AJCC 7th edition. The statistics shown in 
Fig 1 was prior to the formal recommendation of the 
minimum number of LNs sampled at surgery, it is 
conceivable that some of those Stage IIb disease patients 
were in fact understaged Stage III using the most recent 
recommendations. With a robust denominator in place, 
the accuracy of disease staging is improved when 
coming to design of future clinical trials for adjuvant 
colon cancers. 
Fig 3 Summary of the key changes made for staging between AJCC 
6th and 7th edition
In response to the advances made, the AJCC has 
published a revised staging guide in 2010. The summary 
of the key changes in staging is summarised in Fig 3 and 
the survival analysis based on the 6th and 7th edition 
staging system is shown in Fig47-8. The introduction of a 
T4 a and b stage takes into account of tumour invasion 
and adherence to adjacent organs which is related to 
worsened outcome of resected CRCs. There will be an 
inclusion of minimum number of LNs sampled. The 
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revised staging proposal was tested against the current 
6th edition. The results yielded a surprising amount of 
changes in the prognostic outcome between the old 6th 
edition and the proposed 7th edition.9 It is estimated 
that up 25% of the newly diagnosed LSCCs will have 
their treatment decision altered as a result of the 7th 
edition. As a result, the clinical trials designed using the 
7th edition of AJCC staging should not be compared 
retrospectively to the trials based on earlier editions.
Other Risks Factors Used in LSCC 
Risk Stratification
Many attempts have been made to augment and 
improve on the accuracy of the predictive value of the 
TNM staging system. The aim is to find better surrogate 
markers to segregate the otherwise homogenous disease 
with equal TNM stage into those who are at different 
risk of disease recurrence. The most common ones used 
are listed below
1) Tumour perforation at resection
2) High tumour grade/ Lack of tumour differentiation
3) Lymphovascular invasion
4) Bowel obstruction
5) Neurovascular invasion
6) Inadequate LN sampling
Clinical Trial Groups have incorporated clinical 
characteristics listed and produced nomograms for 
predicting relapse risks for early CRCs. These include 
the nomogram by Weiser10 and the Adjuvant on line 
[http://www.adjuvantonline.com] type risk calculators. 
These tools are invaluable in the clinical discussion of 
the use of adjuvant chemotherapy in preventing disease 
recurrence in LSCCs. 
Novel Predictive Biomarkers is an 
Urgent Unmet Medical Need in Colon 
Cancer
There is an urgent need to develop a set of prognostic 
markers which can give useful information regarding 
the likelihood of disease relapse in LSCCs. Since some 
of the high risk features are directly related to the time 
lag in making the diagnosis of colon cancer, it would be 
most useful to have available markers which are based 
on intrinsic tumour biology. Of equal importance, there 
also needs to be a set of predictive markers which can 
be utilised to select patients who are likely to respond 
to therapy being tested in colon cancer. The strategy 
of combining prognostic and predictive markers can 
revolutionalise clinical trial designs to select enriched 
population for responders and select high risk patients 
to capitalise on the novel developments in therapeutics.
In the field of breast cancer, there are currently multiple 
validated molecular tests which can greatly aid 
physicians in making treatment decisions for adjuvant 
breast cancers. It would provide a much needed boost 
for fighting colon cancers if we have available similar 
tests for evaluating relapse risks for colon cancers. 
Molecular tests in development and testing are 
summarised in Table 1.
Table 1 Summary of markers undergoing evaluation in adjuvant 
Colon Cancers.
Molecular 
Marker
Material required Method used Prospective 
validated
Nature
CEA Serum ELISA based Yes Prognostic
GCC22 Fixed tumour tissue PCR Yes Prognostic
Circulating 
tumour 
DNA23,24
Plasma PCR based ? Prognostic
MSI25 Fixed tumour tissue Immuno-
histochemistry
Yes Prognostic 
but may 
also be 
predictive*
18q LOH Fixed tumour tissue PCR Yes Prognostic
Gene signature11 Frozen tissue Gene 
expression 
array
No Prognostic
LDH Serum ELISA No Predictive
k-Ras16 Fixed tumour tissue PCR No Predictive
b-Raf26 Fixed tumour tissue PCR No Predictive
Fig4 Survival according to Staging between AJCC 6th vs 7th
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Currently there are no data to recommend the use of 
molecular markers in the decision making process 
for adjuvant therapy of CRCs. Loss of heterozygosity 
at  chromosome 18q (LOH18q) and the lack of 
microsatellite instability (MSI) are potential markers 
for aggressive clinical disease. These markers will be 
tested in ECOG5202 where Stage II colon cancers are 
first assayed for recurrence risks based on 18q and 
MSI status. Those who fall in the high risk category 
are prospectively stratified to treatment with FOLFOX 
(5-fluorouracil [5-FU]/leucovorin[LV]/oxaliplatin) with 
or without the addition of bevacizumab. The low-risk 
patients are assigned to surveillance alone. This trial is a 
landmark in adjuvant CRC trial since it will be the first 
to test a molecular prognosticator for decision making 
in adjuvant CRC. 
In constructing a trial like ECOG 5202, it is provocative 
to test the reliability of a novel biomarker to predict 
the clinical outcome. Traditional Stage II disease does 
not benefit from adjuvant therapy taken as a group. 
Subjecting the patients to risk stratification prospectively 
and then selecting the high risk group for therapy 
enriches a subset of patients who may show differential 
benefits from adjuvant therapy. 
Tumour Biology Based Testing
The most ambitious test of all is probably the expression 
array or gene panel RT-PCR based assay which 
investigates the biology of colon cancers where certain 
molecular signatures are identified and their clinical 
outcome correlated. 
The more robust test is likely to be RT-PCR based 
test similar to the oncotype RX 21 gene signature 
set used in breast cancers. This test can be done in 
archival materials and does not require fresh tissue 
preservation unlike the expression array based which 
requires snap frozen materials which limit the general 
availability of the test across a mixture of community 
and specialised hospitals dealing with colon cancer 
care. In ASCO 2009, there was a presentation of a RT-
PCR based tumour recurrence score. It utilised 4 large 
prospective studies as the training set and an 18 gene 
panel was ultimately used in the validation study. The 
validation sample came from the QUASAR adjuvant 
colon cancer trial where 90% of the 3238 patients were 
Stage II are randomised to be treated with 5FU based 
chemotherapy or observation alone. The preliminary 
report showed that this Oncotype colon test has 
demonstrated a predictive role in determining relapse 
likelihood for resected Stage II disease11. This marks a 
major breakthrough in risk prediction in adjuvant colon 
cancers since the introduction of TNM staging with 
revised LN sampling recommendation.
Defining the End Point for Adjuvant 
Studies in the Era of Biological 
Therapies
The goal of adjuvant therapy is to eliminate potential 
micrometastatic disease and ensure the patient leads 
a cancer free life after completion of chemotherapy. In 
practice however, with the advancing age of the general 
population and the increasing number of elderly 
patients diagnosed with colon cancer, disease free 
survival (DFS) at 3 year is adopted as a surrogate with 
good supporting data12. The ACCENT group further 
reported another meta-analysis incorporating the latest 
adjuvant trials for Stage III patients which utilised oral 
fluoropyrimidines, oxaliplatin, and irinotecan in ASCO 
200913. They concluded that 2yr DFS is an excellent 
surrogate for 5 yr and 6 yr OS. Incidentally, the FDA 
had accepted 3 yr DFS as acceptable clinical end point 
for trial design for future approval of adjuvant therapy 
for colon cancers.
NSABP C-08 is a trial that aimed to investigate the 
addition of bevacizumab, an anti VEGF-a antibody 
which has demonstrated substantial benefits in the 
metastatic setting to the standard of FOLFOX 6 for the 
treatment of Stage II and III colon cancers. The much 
anticipated results were published14. It was sobering to 
learn that there was no benefit seen at all at the accepted 
time point of DFS at 3 years. In the exploratory analysis, 
there were no differences between Stage II and III 
patients. Despite a very significant DFS at 1 year, as the 
trial matured, the DFS between the experimental arm 
and the standard arm gradually came together at the 3 
yr mark14. This result should strike a cautionary note to 
clinical trial groups, whilst DFS is a reliable end point 
in chemotherapy based adjuvant colon cancer trials, 
this may not be the case in the era of targeted therapy. 
Bevacizumab does deliver a statistical advantage at 
follow ups during year 1 and 2 but negative results at 
3 years. This was confirmed by a recent presentation of 
the AVANT trial using a similar study design but carried 
out in Europe15.
The superior year 1 and 2 outcome of the bevacizumab 
containing arm in the 2 trials tells us that the combination 
is effective in prolonging disease relapse by radiological 
measures. However, with time, microscopic tumour 
deposits will be triggered into a growth phase and 
develop into radiological apparent metastatic disease. 
The bevacizumab-FOLFOX combination contributes no 
further benefit in eradicating these microscopic deposits 
compared with FOLFOX. Therefore, one can consider 
this combination is more tumour static but not more 
tumourcidal. This could explain the difference in efficacy 
between the metastatic and adjuvant setting. This novel 
phenomenon needs to be taken into account when 
designing future clinical trials.  
Therapeutic Differences Between 
Adjuvant and Metastatic Colon cancer
Adjuvant chemotherapy for cancer has generally been 
the adaptation of effective regimens used in metastatic 
setting and testing them for efficacy in the adjuvant 
setting. The adjuvant therapy for colon cancer has 
reached some rather unexpected conclusions. CPT11 
or irinotecan, a very effective drug in the metastatic 
setting, failed in the adjuvant setting despite its proven 
role in the management of metastatic disease. Multiple 
trials have repeatedly failed to show additional benefits 
when it is combined with the older standard of 5 FU/
Leucovorin17. 
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It is also becoming apparent in colon cancers that 
certain genetic mutations carry predictive power to the 
response to given therapy. For example, k-Ras mutants 
have been shown to derive no benefit from agents 
targeting the EGFR signalling pathway16. Furthermore, 
it is now known that downstream b-Raf status is also 
critical in predicting response to EGFR targeting agents 
in metastatic CRCs17. 
A fraction of the NCCTG N0147 trial was reported 
earlier this year18. This part tested the combination 
of FOLFIRI alone or with the addition of Cetuximab, 
a highly effective combination in metastatic colon 
cancers19. The FOLFIRI Cetuximab combination yielded 
a disease free survival which is disappointingly lower 
than the standard of FOLFOX4 even for the k-RAS wt 
patients. 
To further add to this confusion, the ill-fated NCCTG 
N0147 trial where prospectively selected k-RAS wt 
patients were randomised to FOLFOX with or without 
Cetuximab. The results were again disappointing 
because there was no benefit in adding Cetuximab 
for this group of patients20. The fate of the utility of 
Cetuximab in adjuvant colon cancers will rest with 
the results of the PETACC 8 trial which has completed 
recruitment and results are eagerly awaited.
Conclusion
Development of adjuvant therapy for early colon 
cancers has hit an unfortunate road block. Whilst there 
was a quantum leap in terms of disease control and 
overall survival during the past 10 years for metastatic 
disease, the recent reports of multiple failed trials 
trying to incorporate these advances in the adjuvant 
setting is perplexing and disappointing.  Since the target 
of adjuvant chemotherapy is the disseminated non-
measurable tumour cells, their response to targeted 
therapy may not mirror that of larger macroscopic 
disease. Whilst the biology of micrometastases is 
beyond the scope of this review, factors like cell cycle 
status, tumour dormancy, cancer stem cell biology, 
pharmacodynamics and pharmacokinetics may explain 
some of the differences seen in efficacy.
Looking ahead, in addition to prognostic markers, 
response predictors are essential in guiding the 
appropriate selection of patients who are likely to 
benefit from adjuvant therapy in the future. In order to 
be effective, we must address the difficult problem of 
personalised adjuvant chemotherapy decision.  
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SUN6 Miss Alice TANG; Miss Sharon HUNGTel: 2527 8285
HKMAPS 1st Photo Competition & Sharing Session 2011
Organiser: The Hong Kong Medical Association Photographic Society, Venue: HKMA 
Head Office, 5/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Hong Kong
2:00 pm 
TUE8 Miss Carman WONGTel: 2527 8285HKMA CMS 3X Briefing SessionOrganiser: HKMA CMS Club, Speaker: Mobigator Technology Group, Venue: The HKMA Dr. Li Shu Pui Professional Education Centre, 2/F, Chinese Club Building, 21-22 Connaught 
Road Central, Hong Kong
1:00 pm 
FRI11
Miss Candice TONG
Tel: 2527 8285
HKMA Shatin Doctors Network CME – Advances in the Management of Allergic Rhinitis
Organiser: HKMA Shatin Doctors Network, Chairman: Wilson Yee-leung FUNG, Speaker: 
Prof. Gary Wing-kin WONG, Venue: 2/F, Jasmine Room, Royal Park Hotel,  Shatin, NT
1:00 pm 
MON7
Dr. Hing-hoi HUNG / 
Ms. Tammy HUNG 
Tel: 2958 6006 / 9609 6064
Fax: 2958 6076 / 8344 5115
1 CME Point (for The College of 
Surgeons of Hong Kong)
(1) Heal Replacement of the Ureter
(2) Management of Ureteric TCC in an Elderly Male 
Oganiser: Hong Kong Urological Association, Chairman: Dr. Ida Soo-fan MAH, Speakers: 
Dr. Wai-sang WONG & Dr. Ida Soo-fan MAH, Venue: Seminar Room, G/F, Block A, Queen 
Elizabeth Hospital, Kowloon 
7:30 pm - 8:00 pm 
SAT5 Miss Viviane LAMTel: 2527 84522.5 CME Points
MPS – Mastering Professional Interactions
Organiser: The Hong Kong Medical Association, Speakers: Various, Venue: Kowloon & 
Hong Kong 
2:00 pm 
THU
TUE
Miss Viviane LAM
Tel: 2527 8452
1 CME Point1
WED2
THU3
HKMA Tai Po Community – Early Detection of Dementia in the Family and Medical 
Treatment Abstract
Organiser: HKMA Tai Po Community Network, Speaker: Dr. David Lok-kwan DAI, 
Venue: Tai Po
Ms. Sonia CHEUNG 
Tel: 2527 8898    Fax: 2865 0345
FMSHK Officers’ Meeting
Organiser: The Federation of Medical Societies of Hong Kong,   Venue: Gallop, 2/F., Hong 
Kong Jockey Club Club House, Shan Kwong Road, Happy Valley, Hong Kong 
Ms. Christine WONG
Tel: 2527 8285
HKMA Council Meeting
Organiser: The Hong Kong Medical Association, Chairman: Dr. K Choi, Venue: HKMA 
Head Office, 5/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Hong 
Kong
Secretariat
Tel: 2572 9255
25 CNE/PEM Points
Certificate Course in Urology Nursing (Code No. TC-UN-11-01)
Organiser: College of Nursing, Hong Kong
Date  / Time Function Enquiry / Remarks
1:45 pm 
8:00 pm – 10:00 pm
6:30 pm – 9:30 pm 
(9,16,23,30)
FRI4
Department of Surgery, Hong 
Kong Sanatorium & Hospital
Tel: 2835 8698    Fax: 2892 7511
1 CME Point (Active)
Joint Surgical Symposium - Vascular Surgery and Recurrent Disease
Organiser: Department of Surgery, The University of Hong Kong & Hong Kong 
Sanatorium & Hospital, Chairman: Dr. Lik-Cheung CHENG, Speakers: Prof. Stephen 
CHENG & Dr. Yiu-Che CHAN, Venue: Hong Kong Sanatorium & Hospital
8:00 am - 9:00 am
(10,15)
(12,19,23)
Ms. Candy YUEN
Tel: 2527 8285
HKMA Choir Rehearsal
Organiser: The Hong Kong Medical Association, Venue: GP1, HKCC
8:00 pm 
(14,21,28)
(23,30)
WED9 Dr. Gilberto LEUNGTel: 2255 3368   Fax: 2818 43501.5 CME Points (The College of 
Surgeons of Hong Kong)
Hong Kong Neurosurgical Society Monthly Academic Meeting, Special Lecture – State of 
the Art Technology in Stereotactic RadioSurgery and Radiotherapy
Organiser: Hong Kong Neurosurgical Society, Speaker: Miss Victy WONG, Venue: Seminar 
Room, Ground Floor, Block A, Queen Elizabeth Hospital
Miss Carman WONG
Tel: 2527 8285
1 CME Point
HKMA CW&S CME - Certificate Course on Dermatology (Session 2)
Organiser: HKMA - CW&S Community Network, Chairmen: Dr. Yim-kwai LAW; Dr. 
Sabrina Lai-ching HO & Dr. Ping-yin YIK, Speakers: Dr. Louis Tai-cho SHIH; Dr. 
Kuen-kong LO & Dr. William Yuk-ming TANG, Venue: The HKMA Dr. Li Shu Pui 
Professional Education Centre, 2/F, Chinese Club Building, 21-22 Connaught Road Central, 
Hong Kong
Miss Viviane LAM
Tel: 2527 8452
2.5 CME Points
MPS – Mastering Your Risk Workshop
Organiser: The Hong Kong Medical Association, Dr. Ka-lam HAU, Venue: Hong Kong
7:30 am 
1:00 pm 
6:00 pm 
(10,17,24,31)
Ms. Candice TONG
Tel: 2527 8285
1 CME Point 
HKMA YTM Community Network CME- Screening and Investigation of Prostate Diseases
Organiser: HKMA YTM Community Network, Chairman: Dr. Chung-ping HO, MH, JP, 
Speaker: Dr. Byron Bok-wai WONG, Venue: Pearl Ballroom, 2/F, Eaton Smart, Hong Kong, 
380 Nathan Road, Kowloon
Ms. Portia LEE
Tel: 2606 8426    Fax: 2506 2537
Email: portia.lee@sanof-aventis.com
Website: http:// www.oshk.org.hk
Practical Considerations in the Treatment of Osteoporosis and New Findings with 
Bisphosphonates
Organiser: Osteoporosis Society of Hong Kong, Speaker: Prof. John EISMAN (Australia), 
Venue: Ballroom Four, 18/F , the Mira Hong Kong
1:00 pm 
6:30 pm -10:00 pm 
Ms. Candice TONG
Tel: 2527 8285
1 CME Point
HKMA – HK East Community Network – Quadrivalent HPV Prevention – More than 
Cervical Cancer Prevention
Organiser: HKMA – HK East Community Network, Chairman: Dr. Bernard Bun-lap 
WONG, Speaker: Dr. Kar-fai TAM, Venue: HKMA Head Office, 5/F., Duke of Windsor 
Social Service Building, 15 Hennessy Road, Hong Kong
1:00 pm
Ms. Gary WONG
Tel: 3513 5548
1 CME Point
HKMA – KLN East Community Network; HA – UCH; HKCFP – CME Course for Health 
Personnel 2011
Organiser: HKMA – KLN East Community Network, Chairman: Dr. Man-wo TSANG, 
Speaker: Dr. Chi-sang HUNG, Venue: Lei Garden Restaurant, APM, Kwun Tong (Pending)
Miss Carman WONG
Tel: 2527 8285
HKMA NTW CME - Certificate Course on Diabetes Mellitus (Session 1 – Session 3) 
Organiser: HKMA NTW Community Network, Chairmen: Dr. Alvin Kwok-wai CHEUNG; 
Dr. Charlie Kam-sun YAN & Dr. Aaron Fook-kay LEE, Speakers: Dr. Ernest Ngai-pang 
WONG & Dr. Gary Tin-choi KO, Venue: Plentiful Delight Banquet (????????)1/F, 
Ho Shun Tai Building, 10 Sai Ching Street, Yuen Long, New Territories (Pending)
1:00 pm
1:00 pm
Miss Y.C. YEUNG                                                        
Tel: 3119 1858    Fax: 2301 2414        
27 CNE Points
中醫藥理論精華與中西醫給合專題療護課程
Organiser: Hong Kong Association for Integration of Chinese-Western Medicine, 
Chairman: Dr. Edwin Chau-leung YU, Venue: SGN, G/F., Room 08, Queen Elizabeth 
Hospital, 30 Gascoigne Road, Kowloon  
7:00 pm – 10:00 pm
8:00 pm 
2:00 pm Miss Viviane LAM
Tel: 2527 8452
1 CME Point10 HKMA Structured CME Programme with Hong Kong Sanatorium & Hospital Year 2011 – Common Knee InjuriesOrganiser: The Hong Kong Medical Association, Chairman: Dr. Bun-lap WONG, 
Speaker: Dr. Jimmy Wai-kwok WONG, Venue: The HKMA Dr. Li Shu Pui Professional 
Education Centre, 2/F, Chinese Club Building, 21-22 Connaught Road Central, Hong 
Kong
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SUN
Ms. Dorothy KWOK
Tel: 2527 828520 HKMA Football Day 2011Organiser: The Hong Kong Medical Association, Venue: CUHK12:00 pm 
MON
Secretariat
Tel: 2572 9255
12 CNE/PEM Points21
Workshop of Touch & Infant Massage for Nursing Professionals (Code No. 
WS-TIM-11-01)
Organiser: College of Nursing, Hong Kong
6:30 pm – 9:30 pm 
(28)
THU
Ms. Candy YUEN
Tel: 2527 828531 HKMA Choir Family Concert Organiser: The Hong Kong Medical Association, Venue: Theatre, Sheung Wan Civic Centre8:00 pm 
SAT
Miss Viviane LAM
Tel: 2527 8452
2 CME Points12
SUN13
Refresher Course for Health Care Providers 2010/2011
Organiser: The Hong Kong Medical Association, Dr. Tin-sik CHENG, Venue: OLMH
Miss Viviane LAM
Tel: 2527 8452
2.5 CME Points
MPS – Mastering Adverse Outcomes Workshop
Organiser: The Hong Kong Medical Association, Speaker: Dr. Ares LEUNG, Venue: 
Kowloon
Miss Viviane LAM
Tel: 2527 8452
3 CME Points
HKMA Certificate Course on Family Medicine 2011
Organiser: The Hong Kong Medical Association, Speakers: Dr. Yee-shing CHAN & Dr. 
Hung-hing TSE, Venue: Queen Elizabeth Hospital, Kowloon 
Date  / Time Function Enquiry / Remarks
2:30 pm 
TUE
Ms. Sonia CHEUNG 
Tel: 2527 8898    Fax: 2865 034515 FMSHK Executive Committee Meeting  Organiser: The Federation of Medical Societies of Hong Kong, Venue: Council Chambers, 4/F., Duke of Windsor Social Service Building, 15 Hennessy Road, Wanchai, Hong Kong
8:00 pm – 10:00 pm 
FRI
Ms. Candice TONG
Tel: 2527 8285
1 CME Point 18
HKMA Shatin Doctors Network CME – Common Eye Disease in GP Practice and 
Management
Organiser: HKMA Shatin Doctors Network, Chairman: Dr. Wilson Yee-leung FUNG, 
Speaker: Dr. Albert WONG, Venue: 3/F, Jasmine Room, Royal Park Hotel,  Shatin, NT
1:30 pm 
2:00 pm 
2:00 pm 
Ms. Dorothy KWOK
Tel: 2527 8285
HKMA Photographic Society – The Magic of Migration (Photo Shooting Tour)
Organiser: The Hong Kong Medical Association Photographic Society, Venue: Mai Po
9:00 am 
Course / Meeting
18th Asian Congress of Surgery & 37th Philippine College of Surgeons Mid-year Convention
Organiser: Asian Surgical Association, Venue: Waterfront Cebu City Hotel & Casino, Lahug, Cebu City, Philippines, Enquiry: 
Congress Secretariat, Tel: (632) 9274973-74; (632) 9281083; (632) 9292359, Fax: (632) 9292297, E-mail: secretariat@acs2011.org, 
Website:  http://www.acs2011.org
12-14/5/2011
Upcoming Certificate Courses of the Federation of Medical Societies of Hong Kong
01/04/2011 - 13/05/2011
06/04/2011 - 11/05/2011
Medical and Health Professionals
General Practitioners, Health 
Care Providers and Public Who 
Are Interested in Common 
Kidney Problems in Children
9 CNE Points; CME/CPD 
Accreditation in application
9 CNE Points; CME/CPD 
Accreditation in application
Certificate Course on 
Management of Common 
Psychiatric Disorders 2011 
Certificate Course on Paediatric 
Nephrology 2011
C173
C176
Date Course No Target ParticipantsCourse Name CME/CNE 
News from Member Societies
1. Hong Kong Society of Cytology
Updated office-bearers for the year 2010-2011 are as follows: President: Dr. Yue CHENG; Honorary Secretary: 
Ms. Kit-yee LEE; Honorary Treasurer: Ms. Yin-yee SO
2. The Hong Kong College of Family Physicians
Updated office-bearers for the year 2010-2011 are as follows: President: Dr. Ruby LEE; Honorary Secretary: Dr. 
Tung-chi LAW; Honorary Treasurer: Dr. Ho-lim LAU
3. The Hong Kong College of Psychiatrists
Updated office-bearers for the year 2010-2012 are as follows: President: Prof. Linds LAM; Honorary Secretary: 
Dr. W. H. CHEUNG; Honorary Treasurer: Dr. Victoria TANG
The FMSHK would like to send its congratulations to the new office-bearers and look forward to working 
together with the societies.   
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Answer to Dermatological Quiz
1.
2.
3.
4.
Isotretinoin-induced pyogenic granuloma-like lesions
The main differential diagnosis is acne fulminans. Other 
possibilities include gram-negative folliculitis and 
pyoderma, although these usually do not give rise to the 
haemorrhagic lesions.
This uncommon side-effect of oral isotretinoin was more 
frequently seen in patients receiving high dose regimen 
in the past. In fact, it is much less seen in recent years as 
low-dose regimen of oral isotretinoin is more frequently 
used now in the treatment of acne. To minimise the 
chance of these exuberant granulation tissues, one can use 
a lower starting dose in patients presented with markedly 
inflammatory acne, together with the cover of an oral 
macrolide during the first month of treatment. Once the 
condition is stable, the dosage of oral isotretinoin can then 
be increased if necessary. In acne fulminans, concomitant 
use of prednisolone is often needed, especially in the 
initial phase.
Strong teratogenicity, hepatic dysfunction like elevated 
liver enzymes, hyperlipidaemia, skeletal abnormalities 
like DISH (diffuse idiopathic skeletal hyperostosis) or 
rarely benign intracranial hypertension (pseudotumor 
cerebri) should be watched out. In recent years, anecdotal 
reports suggested a causal association between oral 
isotretinoin and severe depression has led to new 
blackbox warning and medicolegal implications of this 
drug. However, this has not been proven by subsequent 
more evidence-based researches. A systemic review 
of studies comparing depression before and after 
treatment with isotretinoin did not find a statistically 
significant increase in this morbidity.1 In addition, a large 
population-based cohort study did not show evidence 
for a causal link between isotretinoin exposure and an 
increased risk of newly diagnosed depression, suicidal 
behaviour, psychosis or other psychiatric disorders.2 In 
practice, psychiatric morbidities are far more common 
in patients with uncontrolled or severe acne than those 
treated with oral isotretinoin.
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